Bringing the biorefinery concept to the health-care facilities: use of industrial by-products against multi-drug resistant bacteria by Rosa, Daniela Filipa Firmino
  
Daniela Filipa Firmino Rosa 
 
Graduation in Biochemistry  
 
 
 
 
 
 
Bringing the biorefinery concept to the health-care 
facilities: use of industrial by-products against 
multi-drug resistant bacteria 
  
  
Dissertation to obtain the Master degree in Biochemistry 
 
  
  
  
  
Supervisor: Doctor Paula Cristina Castro Parreira e Guerra, CEBAL 
 
Co-supervisor: Doctor Andreia Patrícia Henriques Ascenso, Faculdade de 
Farmácia - UL 
 
 
 
 
 
 
 
 
Jury: 
 
President: Prof. Doctor José Ricardo Franco Tavares 
 
Examiner: Prof. Doctor Maria Luísa Lopes de Castro e Brito 
 
Vowel: Doctor Paula Cristina Castro Parreira e Guerra               
 
 
 
 
 
 
 
  
  
 
October 2016 
 
  
 
 
 
 
         
 
 
 
 
Daniela Filipa Firmino Rosa 
 
 Graduation in Biochemistry  
 
 
   
Bringing the biorefinery concept to the health-care 
facilities: use of industrial by-products against 
multi-drug resistant bacteria 
  
  
Dissertation to obtain the Master degree in Biochemistry 
 
  
  
  
 
Supervisor: Doctor Paula Cristina Castro Parreira e Guerra, CEBAL 
 
Co-supervisor: Doctor Andreia Patrícia Henriques Ascenso, Faculdade de 
Farmácia - UL 
 
 
 
 
 
Jury: 
 
President: Prof. Doctor José Ricardo Franco Tavares 
 
Examiner: Prof. Doctor Maria Luísa Lopes de Castro e Brito 
 
Vowel: Doctor Paula Cristina Castro Parreira e Guerra               
 
 
 
 
 
October 2016 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bringing the biorefinery concept to the health-care facilities: use of industrial by products 
against multi-drug resistant bacteria 
 
 
Copyright © DANIELA FILIPA FIRMINO ROSA, Faculdade de Ciências e Tecnologia,  
Universidade Nova de Lisboa. 
 
A Faculdade de Ciências e Tecnologia e a Universidade Nova de Lisboa têm o direito, perpétuo e sem 
limites geográficos, de arquivar e publicar esta dissertação através de exemplares impressos 
reproduzidos em papel ou de forma digital, ou por qualquer outro meio conhecido ou que venha a ser 
inventado, e de a divulgar através de repositórios científicos e de admitir a sua cópia e distribuição com 
objetivos educacionais ou de investigação, não comerciais, desde que seja dado crédito ao autor e 
editor. 
 
 
i 
 
Agradecimentos 
 
A todos aqueles que de uma forma direta ou indireta contribuíram para a concretização deste 
trabalho quero deixar o meu sincero agradecimento.  
 
Em primeiro lugar, como não poderia deixar de ser, quero deixar o meu maior e mais sincero 
agradecimento à Doutora Paula Parreira, por ter aceite ser minha orientadora neste trabalho, 
pelo apoio incondicional prestado, pelas palavras de incentivo, dedicação, paciência e sincera 
amizade. Foi um enorme privilégio tê-la como orientadora! 
 
Quero agradecer à Doutora Fátima Duarte por me ter aberto as portas do CEBAL há dois 
anos atrás, pela confiança que em mim depositou para integrar no seu grupo de investigação, 
onde pude desenvolver conhecimento e competências na área de investigação. Pelo incentivo 
em ingressar no mestrado e pela constante contribuição no decorrer deste trabalho de 
investigação. Muito obrigada!  
 
Ao CEBAL por me ter dado todas as condições para a realização deste trabalho, bem como 
aos projetos Neukbark, RefinOlea e ValBioTecCynara por terem cedido as biomassas a utilizar 
neste trabalho de investigação. A todos os investigadores que constituem o CEBAL agradeço 
pelo espírito de entreajuda, com especial agradecimento à Teresa Brás pelo apoio incondicional 
e preocupação; à Olinda Guerreiro, mestre da estatística, pela disponibilidade e ajuda na análise 
estatística deste trabalho; à Ângela Guerra e Ana Paulino pelas palavras de incentivo e 
companhia no nosso laboratório 15; a todas pela amizade e, claro, pelos nossos lanchinhos. Ao 
Miguel Ferro pelas sessões de verão no HPLC há um ano atrás e à Flávia Fernandes pelo 
contributo no último ensaio do meu trabalho. Não posso deixar de agradecer à maltinha da 
bioinformática, Anabel Usié, Brígida de Meireles, Daniel Gaspar e Pedro Barbosa, e à Margarida 
Pereira, pelos cafés matinais, pelos momentos de descontração e pelas after work sessions.  
 
Quero agradecer à FF-UL por me ter dado a possibilidade de desenvolver o meu trabalho 
nas suas instalações. À Professora Doutora Andreia Ascenso, agradeço por me ter recebido com 
a maior simpatia e me ter dado todo o apoio e conhecimento para desenvolver uma das etapas 
deste trabalho. A todos os docentes e investigadores, em especial à Dra. Ana Salgado, pela 
contribuição, palavras de apoio e simpatia, muito obrigada.  
 
À Diretora da Escola Superior Agrária do Instituto Politécnico de Beja, Doutora Maria 
Margarida Pereira, por ter concedido o espaço para a realização da análise sensorial. Ao 
Professor Nuno Bartolomeu Alvarenga, pela disponibilidade para realizar a análise reológica da 
Formulação, pela ajuda e pelo conhecimento transmitido. 
 
ii 
 
Ao Coordenador do Mestrado em Bioquímica, Professor Doutor Ricardo Franco, agradeço a 
oportunidade e o privilégio que tive em frequentar este Mestrado, que muito contribuiu para o 
enriquecimento da minha formação académica e científica. Agradeço também a todos os colegas 
que tive o prazer de conhecer no primeiro ano do Mestrado, com especial agradecimento à Carla 
Varela que tanto me acompanhou, pelos momentos de descontração, por me ter mostrado 
Almada, pela boa disposição, pela amizade; à Ana Diniz pela constante preocupação, por 
arranjar sempre um tempinho na sua agenda super preenchida para estar comigo, pela sincera 
amizade; à Filipa Trovão por estar sempre disponível para ajudar, por nunca se ter esquecido de 
mim depois de ter voltado para a minha cidade, pelo incentivo, pela amizade; à Sara Silva pela 
ajuda na minha integração na faculdade, pelos passeios até à Costa da Caparica que ajudavam 
tanto a desanuviar, pelas longas tardes e noites de estudo no Edifício VII, pela amizade; à Raquel 
Costa pela preocupação e incentivo. Às minhas colegas de casa, Filipa Pereira e Filipa Gomes, 
agradeço por todos os bons momentos que passamos juntas e pela vossa amizade.  
 
Às minhas amizades de Évora, agradeço à Maria Miguel Castro pela amizade sincera, 
constante preocupação e apoio, mesmo quando eu desapareço do mapa, e à Ana Antão por me 
querer levar por bons caminho quando eu a quero levar para os maus. Para além disso, só tenho 
que agradecer por me acompanhar, me apoiar e me motivar sempre que preciso, pela amizade 
para a vida.  
 
Agradeço às minhas amizades mais sinceras, às minhas manas de coração, Ana Raquel 
Barata, Marisa Mendes, Daniela Bica, Cláudia Silva, Tânia Lampreia, Vanessa Gonçalves e 
Adriana Silva, pelo apoio incondicional em todos os altos e baixos. “Os amigos não se escolhem, 
reconhecem-se”… Obrigado!    
 
À minha família, em especial aos meus pais, ao meu irmão e à minha avó Rosária, um 
enorme obrigada por acreditarem sempre em mim e pelo apoio incondicional que sempre me 
deram. Espero que esta etapa, que agora termino, possa de alguma forma retribuir e compensar 
todo o carinho, apoio e dedicação que, constantemente, me oferecem. A eles, dedico todo este 
trabalho. 
 
Financial Support: 
This work was supported by the Program Alentejo 2020, through the 
European Fund for Regional Development under the scope of 
ValBioTecCynara – Economic valorization of Cardoon (Cynara cardunculus): 
study of natural variability and biotechnological applications (ALT20-03-
0145-FEDER-000038). 
 
 
 
iii 
 
Abstract 
Multi-drug resistant bacteria (MDRB) are a public health issue worldwide, being 
alternatives to the conventional failing antibiotherapy required. This fact has turned attention to 
bioactive compounds with antimicrobial activity features. These bioactives can be extracted from 
several biomasses sources, namely industrial by-products, within a biorefinery concept.  
 
The main objective of this Thesis was the design of a novel antiseptic formulation (AF), 
based on natural plant extracts, obtained from forest/agriculture industries by-products.  
 
The antimicrobial activities of three extracts from different sources were studied: 
Eucalyptus nitens total bark (ENTB) extract, Cynara cardunculus leaves (CcL) extract and dry 
olive pomace (DOP) extract. Those that presented better antibacterial activity were chosen to be 
included in the AF. Studies regarding formulation design and its antibacterial performance were 
made.  
 
ENTB extract was the one with better anti-MDRB performance, particularly against 
Staphylococcus spp., with minimal inhibitory concentrations between 64 and 2048 µg/mL, being 
included in the AF. The antibacterial activity of ENTB extract-based-AF presented promising 
results, achieving a 97±2% bacterial growth inhibition after exposure to 45% of AF. 
 
In conclusion, the developed AF presents potential to be further investigated, namely for 
hand sanitation within healthcare environment, but additional adjustments should be executed, 
namely in order to turn it more appellative to users. 
 
 
 
 
 
 
 
 
Keywords: Multi-drug resistant bacteria, healthcare-associated infections, antimicrobial activity, 
biorefinery by-products, topical antiseptic formulation. 
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Resumo 
As bactérias multirresistentes a antibióticos (BMRA) são um problema de saúde pública 
a nível mundial, sendo necessárias alternativas à antibioterapia convencional, cuja eficácia tem 
decrescido nas últimas décadas. Este facto atraiu a atenção para compostos bioativos com 
atividade antimicrobiana. Estes bioativos podem ser extraídos a partir de diversas biomassas, 
nomeadamente subprodutos industriais, dentro do conceito de biorrefinaria. 
 
O principal objetivo da presente Tese foi o desenvolvimento de uma nova formulação 
antisséptica (FA), com base em extratos naturais de plantas, obtidos a partir de subprodutos da 
indústria florestal/agrícola. 
 
Para tal, foi estudada a atividade antimicrobiana de três extratos de diferentes origens: 
extrato da casca total de Eucalyptus nitens (ECTEN); extrato de folhas de Cynara cardunculus 
(cardo) e; extrato de bagaço de azeitona seco. Aqueles que apresentaram melhor atividade 
antimicrobiana foram escolhidos para serem incluídos na FA. Estudos de desenvolvimento da 
formulação e desempenho antimicrobiano da mesma foram efetuados. 
 
O ECTEN foi o que apresentou melhor desempenho anti-BMRA, particularmente contra 
Staphylococcus spp., com concentrações mínimas inibitórias entre 64 e 2048 µg/mL, sendo 
incluído na FA. A atividade antibacteriana da FA à base de ECTEN apresentou resultados 
promissores, alcançando 97±2% de inibição de crescimento bacteriano após exposição a 45% 
de FA. 
 
Em conclusão, a FA desenvolvida apresenta potencial para prosseguir para 
investigações futuras, nomeadamente para a higienização das mãos em contexto hospitalar ou 
unidades de cuidados de saúde, mas ajustes adicionais deverão ser feitos, nomeadamente de 
forma a tornar a FA mais apelativa para os utilizadores. 
 
 
 
 
 
 
 
 
Palavras-chave: Bactérias multirresistentes a antibióticos, infeções nosocomiais, atividade 
antimicrobiana, subprodutos de biorrefinaria, formulação tópica antisséptica. 
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1.1 – Infectious diseases: the main players and the challenges in 
the 21st century 
Bacteria are one of the main players in what concerns infectious diseases, to which features 
of high morbidity and mortality are associated. (Zaffiri, Gardner, and Toledo-Pereyra 2012) For 
centuries, the only available resource to treat infections were plants, known to have, among other 
health benefits, antimicrobial activity. (Ríos and Recio 2005) 
In the early 20th century, respiratory infections, like pneumonia and tuberculosis, were the 
leading cause of death. (Sabin 1970) In order to minimize infection spreading, public health 
measures were taken, such as: protection of food and water supplies, improvement of personal 
hygiene and introduction of a vaccination program. (Lederberg 2000) The revolutionary discovery 
of antibiotics as new therapeutic agents was the turning point in the treatment of infectious 
diseases caused by bacteria, allowing to save an uncountable number of lives. (Davies, J, & 
Davies, D. 2010)  
Selman Waksman defined “antibiotic” as any class of organic molecules able to inhibit or kill 
bacterial cells through specific interactions, with low toxicity to the mammalian host. (Davies, J, & 
Davies, D. 2010) In 1928, Alexander Fleming discovered the first effective antibiotic: penicillin. In 
1940s it was introduced in the clinical practice, providing quick and complete treatment of 
previously incurable bacterial diseases. (Davies, J, & Davies, D. 2010) However, antibiotics 
efficiency has been shadowed since the beginning by the ability of bacteria to develop resistance, 
and effectiveness of antimicrobial agents, such as antibiotics, has been decreasing over the 
years. (Lewis 2013) 
According to Instituto Nacional Ricardo Jorge (INSA, Portugal), resistant bacteria are defined 
as immunes (not affected) to the bacteriostatic (inhibits cell proliferation) or bactericidal 
(destruction of the bacterial population) effect of antibacterial agents at its therapeutic dosage. 
(Jorge n.d.) 
 
1.1.1 – Bacterial antibiotic resistance: intrinsic vs acquired mechanisms 
The resistance mechanism to antimicrobial agents, such as antibiotics, can be either intrinsic 
or acquired.  
 
1.1.1.1 – Intrinsic mechanisms 
In intrinsic resistance mechanism, the microorganism has the innate ability to resist to a class 
of antimicrobial compounds. A good example of intrinsic resistance is Pseudomonas aeruginosa, 
a Gram-negative bacteria that is naturally resistant to β-lactam antibiotics, due to the presence of 
a multidrug efflux system and the production of enzymes, β-lactamases, which have the ability to 
hydrolyze the β-lactamic ring. (Lewis 2013) β-lactam antibiotics act on the peptidoglycan cell wall 
synthesis, which in Gram-negative is more difficult to access, since peptidoglycan is present in 
the periplasmic space, between the inner and outer lipid membranes, creating a natural 
3 
 
barrier.(Lewis 2013) In Gram-positive bacteria, the lack of an outer membrane, as well as the 
presence of a thick cell wall, composed by the peptidoglycan layer, (Figure 1.1), makes them 
more susceptible to antibiotics.(Levy and Marshall 2004) 
 
 
 
Figure 1.1. Illustration of structural differences in Gram-positive and Gram-negative 
bacterial cell wall. (State 2002) 
1.1.1.2 – Acquired mechanisms 
In acquired resistance, the microorganisms develop the ability to resist to the antibiotic’s action 
by genetic material alterations, namely mutations or genetic material transference, through mobile 
elements, such as plasmids, bacteriophages, transposons, and others. (Levy and Marshall 2004) 
Antibiotics misuse, which exerts selective pressure upon bacterial populations, contributes to the 
growing appearance of resistance among bacterial strains. According to the Centers for Disease 
Control and Prevention (CDC, USA), the misuse of antibiotics is largely caused by the 
unnecessary or inappropriate antibiotics prescription in 50% of the cases, both in medicine and 
agriculture fields. (“Health Policy Brief: Antibiotic Resistance” 2015) 
 
1.1.2 – Mechanisms of acquired resistance to antibiotics  
There are several pathways by which bacteria may acquire resistance to antibiotics. The 
transference of genetic material is a common event, leading to a cumulative acquisition of 
resistance genes to different antibiotics, in a determined bacterial population. (Lowy 2003) For 
example, methicillin-resistant Staphylococcus aureus (MRSA) acquired resistance to β-lactam 
antibiotics through horizontal gene transference of a resistance gene (mecA), which is 
responsible for the synthesis of a class of penicillin-binding proteins (PBP), which are not sensitive 
to antibiotic inhibition. (Lowy 2003) 
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Since the discovery of the first effective broad-spectrum antibiotic, able to be used against 
different bacteria in therapeutic doses, others have been developed and refined, in order to target 
specific bacteria genre and with defined action mechanisms against bacterial cells. (Davies, J, & 
Davies, D. 2010) Therefore, antibiotics can be grouped in three major categories, according to 
their mechanism of action: cell wall synthesis inhibition; protein synthesis inhibition or nucleic acid 
synthesis inhibition. (Levy and Marshall 2004; McDermott, Walker, and White 2003) 
 
1.1.2.1 – Inhibition of cell wall synthesis 
Cell wall is a distinctive bacterial characteristic and, therefore, it is an excellent target for 
selectively kill or inhibit bacteria in a mammalian organism. The most commonly used inhibitors 
of cell wall biosynthesis are β-lactams (penicillins and cephalosporins) and glycopeptides 
(vancomycin and teicoplanin). (Tenover 2006) 
 
 
Figure 1.2. Peptidoglycan synthesis: (1) synthesis of precursors in the cytoplasm; (2) 
transport of lipid-bound precursors across the cytoplasmic membrane; (3) insertion of 
glycan units into the cell wall; and (4) transpeptidation linking and maturation.(McDermott, 
Walker, and White 2003) (Adapted from Pinho et al.(2013)) 
β-lactams interact with PBP, the enzymes responsible for the generation of the mature 
peptidoglycan. On the other hand, glycopeptides bind peptidoglycan side chains, blocking the 
transglycosylation and transpeptidation reactions necessary to add new subunits to the growing 
peptidoglycan chain (Figure 1.2). (McDermott, Walker, and White 2003) 
The interaction with Gram-negative and Gram-positive bacteria is different: in Gram-positive 
bacteria, the target is more accessible in the outer layer, while in Gram-negative bacteria the drug 
needs to be transported through the outer membrane transport system via proteins (porins). 
(McDermott, Walker, and White 2003) Due to their low permeability, glycopeptides cannot be 
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transported, therefore having limited spectrum of action against Gram-positive bacteria. 
(McDermott, Walker, and White 2003) 
The resistance mechanisms to β-lactams are: i) mutations in the target PBP; ii) acquisition of 
new PBPs with decreased affinity for the drug; iii) production of one or more β-lactamases that 
inactivate the drug; iv) changes in cell wall porins, which limit the drug movement to the target 
site; and v) active efflux of the drug out of the cell by energy-dependent pumps. (McDermott, 
Walker, and White 2003) The resistance mechanism responsible for glycopeptides 
ineffectiveness is the alteration of the amino acid chain target. (McDermott, Walker, and White 
2003) 
 
1.1.2.2 – Protein synthesis 
Protein synthesis is a vital process for cell survival and multiplication. Several types of 
antibacterial agents target the bacterial protein synthesis, by binding to either the 30S or 50S 
subunits of the ribosomes, (Lewis 2013) which leads to the disruption of the normal cellular 
metabolism, resulting in death or growth inhibition. Aminoglycosides (streptomycin and 
gentamicin), chloramphenicol, macrolides (erythromycin) and tetracyclines (tetracycline, 
doxycycline, minocycline) act at the protein synthesis level. (McDermott, Walker, and White 2003) 
The resistance mechanisms associated to these antibiotics are linked to the expression of 
enzymes able to inactive them, either by phosphorylation, adenylation or acetylation; efflux pumps 
or target modification, namely at the ribosome level. (Avent et al. 2011) Gram-negative bacteria 
are intrinsically resistant to macrolides. (McDermott, Walker, and White 2003) 
 
1.1.2.3 – Nucleic acid synthesis 
DNA and RNA are the basic keys for the replication of all living forms, including bacteria. 
Some antibiotics act by binding to nucleotides (sulfonamides) or nucleic acids (quinolones and 
rifamycins), which are involved in the process of DNA or RNA synthesis, causing interference in 
the normal cellular processes and, ultimately, compromising bacterial multiplication and survival. 
(McDermott, Walker, and White 2003) Sulfonamides block the formation of nucleotide precursors, 
by competing with the active site of the enzyme. (McDermott, Walker, and White 2003) In nucleic 
acid synthesis, antibiotics usually act through specific binding to RNA polymerase or DNA 
topoisomerase, like rifamycin and quinolones, respectively. (McDermott, Walker, and White 2003) 
The resistance mechanism associated to sulfonamides is the acquisition of an enzyme with 
low affinity to sulfonamide. (Zaffiri, Gardner, and Toledo-Pereyra 2012) Rifamycin is also 
enzymatically altered, while quinolones have three different resistance mechanisms: target 
modification through mutation of topoisomerase genes; decreased permeability of bacterial cell 
wall or activation of efflux pump. (McDermott, Walker, and White 2003)  
 
In summary, the success of penicillin encouraged the discovery and development of several 
other molecules with antimicrobial activity, either from natural or synthetic origin, against Gram-
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negative, Gram-positive or both, with different action mechanisms, which are summarized in 
Table 1.1. 
Table 1.1. Antibiotics target and resistance mechanisms. 
Class 
(Examples) 
Derivation 
Spectrum 
of 
activity 
Target 
Resistance 
mechanism 
Ref. 
β-lactams 
-Penicillins,  
-Cephalosporins  
-Carbapenems  
N/SS 
Broad-
spectrum 
Cell wall 
synthesis 
inhibitors (PBP) 
Enzymatic 
hydrolysis, efflux 
pump, altered 
target 
(Zervosen 
et al. 2012) 
Aminoglycosides 
-Gentamicin 
-Streptomycin 
N/SS 
Broad-
spectrum 
Protein 
synthesis 
inhibitors (30S 
ribosome) 
Phosphorylation, 
adenylation or 
acetylation, 
efflux pump, 
altered target 
(Shi et al. 
2013) 
Glycopeptides 
-Vancomycin 
N/SS 
Gram-
positive 
Cell wall 
synthesis 
inhibitors 
(Peptidoglycan 
Units) 
Enzymatic 
hydrolysis, efflux 
pump, altered 
target 
(Butler et al. 
2014) 
Tetracyclines 
-Tetracycline 
-Doxycycline 
N/SS 
Broad-
spectrum 
Protein 
synthesis 
inhibitors (30S 
ribosome) 
Enzymatic 
hydrolysis, efflux 
pump, altered 
target 
(Levy and 
Marshall 
2004; 
McDermott, 
Walker, and 
White 2003) 
Macrolides 
-Erythromycin 
-Azythromycin 
N/SS 
Broad-
spectrum 
Protein 
synthesis 
inhibitors (50S 
ribosome) 
Hydrolyze, 
glycosylation, 
phosphorylation, 
efflux pump, 
altered target 
(Leclercq 
2002; Levy 
and 
Marshall 
2004) 
Phenicols 
-Chloramphenicol 
N/SS 
Broad-
spectrum 
Protein 
synthesis 
inhibitors (50S 
ribosome) 
Acetylation, 
efflux pump, 
altered target 
(McDermott, 
Walker, and 
White 2003) 
Sulfonamides 
-Sulfamethoxazole 
S 
Gram-
positive 
Nucleic acid 
synthesis  
inhibitor 
(enzyme 
catalyzes 
formation of 
nucleotides 
precursors) 
Efflux pump, 
altered target 
(Zaffiri, 
Gardner, 
and Toledo-
Pereyra 
2012) 
Rifamycins 
-Rifampicin 
N/SS 
Broad-
spectrum 
Nucleic acid 
synthesis 
inhibitor (RNA 
polymerase) 
ADP-
ribosylation, 
efflux pump, 
altered target 
(McDermott, 
Walker, and 
White 2003) 
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Quinolones 
-Fluoroquinolone 
S 
Broad-
spectrum 
Nucleic acid 
synthesis 
inhibitor (DNA 
topoisomerase) 
Acetylation, 
efflux pump, 
altered target 
(McDermott, 
Walker, and 
White 2003) 
N – Natural; SS – Semi-Synthetic; S – Synthetic  
 
 
1.1.3 – Drug-resistant bacteria in health-care facilities 
1.1.3.1 – ESKAPE 
Multi-drug resistant bacteria (MDRB) are characterized by features of enhanced morbidity 
and mortality. (McDermott, Walker, and White 2003) The ESKAPE (vancomycin-resistant 
Enterococcus, MRSA, β-lactamase of extended spectrum producer Klebsiella, imipenem-
resistant Acinetobacter, imipenem-resistant Pseudomonas spp. and third generation 
cephalosporin-resistant Enterobacter) are a group of prevalent multidrug-resistant strains, that 
greatly concerns the scientific and health-care community, since they are increasingly present in 
health-care facilities, being associated to Nosocomial Infections (NI). (Cars, Hedin, and Heddini 
2011) ESKAPE are highly resistant or even non-responsive to first line drugs recommended for 
their treatment, leading to reduced therapeutic options and to the need of more costly second and 
third line drugs. (Rice 2008)  
In this antibiotic-resistance era, it is a challenging task to the scientific community, as well as 
to the pharmaceutical industry, to identify and develop new, effective, safe and broad-spectrum 
antibacterial drugs. (Brown and Wright 2016) 
 
1.1.3.2 – Nosocomial infections (NI) 
NI, also known as healthcare-associated infections (HAI), are defined as those acquired in/or 
associated with health-care facilities and that were not actively present or in the incubation period 
when patient admission occurred. (Breathnach 2005) According to the World Health Organization 
(WHO), at any given time, the NI prevalence ranges between 5.7% and 19.1%, in low- and middle-
income countries.(World Health Organization 2015) NI are more prevalent in intensive care units 
(ICU), acute surgical and orthopedic wards. (World Health Organization 2015) The core risks 
associated to NI are intensive-care admission, bone marrow transplantation, blood transfusion 
and burn unit. (Zarb et al. 2012) 
NI represent a burden to the 21st century society, reflected in a brutal socio-economical 
impact. NI lead to longer hospitalization periods, more intensive use of hospital’s human 
resources, increased risk for loss of quality of life and even death. (Zarb et al. 2012) The 
economical impact is not only related to the money spent in the above-mentioned scenarios, but 
it is also translated in the loss of working days and consequent production within the active 
population, extended to the patient’s relatives/caretakers. (Breathnach 2005; Fiorentino 2014)  
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As an example, in the USA, approximately 1.7 millions of patients contract a NI, with 100 000 
having death as outcome, being the estimated annual costs associated to NI between 28 to 45 
billions of USD. (Dick et al. 2015) Pneumonia and sepsis, the principal cause of infection related 
to the presence of external devices, like central lines and ventilators, are the most deadly and 
costly infections. (Dick et al. 2015) A 2012 study from the European Centre for Disease Prevention 
and Control (ECDC) highlighted that, per day, 81 089 patients get a NI, resulting in 3.5 million 
patients admitted to ICU annually. (Zarb et al. 2012) The costs related to these numbers are 
translated in 7 billion of € in Europe annually, including direct costs, and reflecting 16 million in 
extra days of hospital stay due to NI. (World Health Organization 2015) 
The growing NI negative impact at different socio-economical levels has propelled the 
introduction of infection control programs. In Europe, in 2004, MRSA was the first bacteria that 
encouraged the creation of surveillance and control programs, in order to reduce resistant 
bacteria in hospital environment. (Breathnach 2005)  
Recently, in Portugal, the number of deaths NI-related have increased, from 2973 in 2010 to 
4606 in 2013. (Direção-Geral de Saúde 2014) Several control measures have been defined such 
as equipment, staff and patients disinfection, screening and monitoring of the occurrence of NI, 
restriction on the use of antibiotics, among others. (Breathnach 2005) 
A 2014 study highlighted that the efforts performed by Health Agencies and the Government 
were able to decrease the incidence of some infections, such as pneumonia-associated with 
tracheal intubation in ICU, bacteremia associated with central venous catheter and infection 
associated with colon and rectal surgery. (Direção-Geral de Saúde 2014) However, there was no 
significant decrease in the number of deaths, with 4500 patients having NI as cause of death. 
(Direção-Geral de Saúde 2014) Regarding antibiotic consumption, there was a positive evolution, 
with 27% and 5% less consumption of quinolones in ambulatory and hospitals, respectively. 
(Direção-Geral de Saúde 2014) Carbapenems use was reduced in 5% in hospitals. (Direção-
Geral de Saúde 2014) Resistance rates associated to some MDRB, such as MRSA, 
Enterococcus spp. and Acinetobacter spp. have began to decrease. (Direção-Geral de Saúde 
2014) Nonetheless, there is still great concern regarding the Gram-negative microorganisms, 
being quinolones-resistant E. coli and carbapenems-resistant Klebsiella spp. the main players. 
(Direção-Geral de Saúde 2014) Over the last couple of years, outbreaks of NI by K. pneumoniae, 
which resulted in dozens of deaths, were reported. (Borja-Santos 2016; Direção-Geral de Saúde 
2014) Every day, it is estimated that 12 patients die from NI caused by either E. coli or Klebsiella 
spp., a higher mortality rate than that of car crashes. (Madrinha 2016) However, despite all the 
efforts made, Portugal remains with one of the darkest European scenarios in what concerns NI. 
(Direção-Geral de Saúde 2014) 
Among the several control measures implemented in hospitals, it was determined that the 
simplest but yet most effective preventive action is hand hygiene, with water and soap or with 
alcoholic-based solutions, allowing to prevent cross infections. However, adherence to this 
countermeasure is low among hospital staff for different reasons, such as: skin irritation due to 
disinfectants agents; forgetfulness; use of gloves; insufficient time for cleaning; lack of knowledge 
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of this effective measure; among others stated. (Pittet 2001) It is thought that the introduction of 
new disinfectants agents, with more attractive features, may improve the compliance to this 
simple but yet highly effective measure for NI prevention. (Pittet et al. 2000)  
 
 
1.2 – Phytotherapy: use of bioactive compounds as therapeutic 
tools 
Plants have been used in folk medicine for centuries, from a trial and error strategy, in an 
initial form of crude drugs such as tinctures, teas, poultices, powders, infusions, to more recent 
and advanced formulations, tested with scientific methods. (Balunas and Kinghorn 2005; Gurib-
Fakim 2006) Plants produce a wide range of bioactive compounds with diverse physiological and 
functional roles, such as defense mechanisms, pigments that attract pollinators of flowers, UV 
protection mechanisms (flavonoid, anthocyanin, etc.) and oxidative stress (phenolic compounds). 
(Simões, Bennett, and Rosa 2009) In defense mechanisms, a wide range of compounds that 
exhibit a huge chemical diversity are present, such as glycosteroids, flavonoids, terpenes and 
isoflavones. (Simões, Bennett, and Rosa 2009) Few infections occur in plants, which may be 
linked to the presence of a highly effective innate defense mechanism. (Abreu, McBain, and 
Simões 2012) The scientific advance in the phytotherapy field allowed to further uncover plants 
biological potential, highlighting its benefits and therapeutic actions associated to their chemical 
composition (bioactive compounds). (Gurib-Fakim 2006) A bioactive compound is usually a 
plant’s secondary metabolite, able to trigger pharmacological and/or toxicological effects in 
humans and/or animals, such as: anti-inflammatory; antioxidant; antibacterial; antifungal; 
antitumor among others. (Simões, Bennett, and Rosa 2009) They can act individually, additively 
or synergistically and have several biological activities attributed. (Gurib-Fakim 2006) 
The decrease of conventional antibiotics effectiveness and the high costs to pharmaceutical 
industries for the development of new drugs, has contributed to the renewed interest in 
phytopharmaceuticals. (Abreu, McBain, and Simões 2012) An example of a commercialized drug 
obtained from natural sources is TAXOL®, and its derivative paclitaxel, anti-cancer and anti-
malaria drugs, which are synthesized from the bark of the yew tree (Taxus brevifolia). (Expósito 
et al. 2009) 
Bioactive compounds antimicrobial performance against bacterial cells has been previously 
studied, demonstrating activity against a broad array of pathogenic microorganisms, including 
MDRB. (Simões, Bennett, and Rosa 2009) Despite the antimicrobial potential of bioactive 
compounds, increased by its diversity and structural complexity, none is currently used as 
antibiotic. (Gibbons 2004) Nonetheless, there is evidence that bioactive compounds are able to 
potentiate antibiotic action against MDRB, a promising result for inclusion in the currently available 
antibiotherapy. (Abreu, McBain, and Simões 2012) Their mechanisms of action are not yet fully 
understood, which may also be linked to the delay of their complete introduction in the 
pharmaceutical field, but evidence points that cell wall degradation, damage in cytoplasmic 
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membrane and membrane proteins, cellular content output, cytoplasm coagulation and depletion 
of the proton motive force, may be responsible for the antibacterial effect. (Cetin-Karaca and 
Newman 2015) 
From the wide range of bioactive compounds reported in the literature, (Cowan 1999) only 
those with relevance within the scope of this Master Thesis will be presented in the following 
sections. 
 
1.2.1 – Phenolic compounds 
Phenolic compounds are secondary metabolites derived from pentose phosphate, shikimic 
acid and phenylpropanoid pathways. (Balasundram, Sundram, and Samman 2006) Structurally, 
they have an aromatic ring with one or more hydroxyl substituents attached. (Gurib-Fakim 2006) 
The molecule complexity can go from the most simple to the highly polymerized compounds. 
(Gurib-Fakim 2006) The most abundant phenolic compounds are conjugated with mono- and 
polysaccharides, attached to one or more phenolic groups, and they may be functionalized with 
esters and methyl esters groups. (Balasundram, Sundram, and Samman 2006) All these 
connections possibilities demonstrate the variety of phenolic compounds classes that may be 
found in nature. (Gurib-Fakim 2006) They are associated with several biological activities, namely 
anti-allergic effect, anti-atherogenic, anti-inflammatory, antitumor, antimicrobial, antioxidant, anti-
thrombotic, vasodilating and cardioprotective. (Balasundram, Sundram, and Samman 2006; 
Gurib-Fakim 2006) Phenols can be found in a great variety of fruits, vegetables, nuts, seeds, 
stems and flowers as well as in teas, wine and honey. (Balasundram, Sundram, and Samman 
2006) They also have an important role in plants physiology and morphology, as well as in 
defense mechanisms and sensorial characteristics. (Balasundram, Sundram, and Samman 2006; 
Cetin-Karaca and Newman 2015)  
Oleuropein, hydroxytyrosol and tyrosol, being the last two degradation products from 
oleuropein hydrolysis, are phenolic compounds that belong to a more specific group, named 
secoiridoids. Oleuropein structure consists in three subunits: elenolic acid, glucose and 
hydroxytyrosol. Hydroxytyrosol and tyrosol structures are based in a phenylethyl alcohol, wherein 
the hydroxytyrosol has one more hydroxyl group than tyrosol (Figure 1.4). (Omar 2010a; 
Rodrigues, Pimentel, and Oliveira 2015) 
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Figure 1.3. Chemical structures of oleuropein, hydroxytyrosol and tyrosol. (Adapted from 
Rodrigues et al. (2015)) 
Oleuropein, and its hydrolysis products, have been associated to a strong antimicrobial 
activity against both Gram-negative and Gram-positive bacteria, as well as against Mycoplasma 
spp. (Omar 2010b) It is accepted that the antibacterial effect may be due to damage to the 
bacterial membrane and/or disruption of the cell peptidoglycan. (Omar 2010b) Other authors 
suggest that the interference in protein synthesis and stimulation of the phagocytose response of 
the immune system are possible mechanisms underlying the antibacterial activity. (Omar 2010b)  
These three compounds can be found in olive tree (Olea europaea L.), mainly in leaves and 
fruits (peel, pulp and seeds), varying their concentration according to the ripeness state. (Wichers, 
Soler-rivas, and Espı 2000) Oleuropein is the most abundant, due to its role in defense 
mechanism, and can reach concentrations of 140 mg/g of green olive dry weight and 60-90 mg/g 
of leaves dry weight. (Wichers, Soler-rivas, and Espı 2000) In olive, the concentration of 
oleuropein decreases according with the ripening state, while hydroxytyrosol and tyrosol 
concentrations increase. (Wichers, Soler-rivas, and Espı 2000) 
 
 
1.2.2 – Terpenes 
Terpenes are natural hydrocarbons with cyclic or acyclic chains isoprene-derived from 
secondary metabolism. (Cowan 1999) Isoprene units (C5) are the building blocks in terpenes 
biosynthesis, forming structures of monomers, dimers or polymers, being its natural precursor 
dimethylallyl pyrophosphate (DMAPP) and its isomer isopentenyl pyrophosphate (IPP). (Dewick 
2002) Hemiterpene (C5) is the simplest terpene. Adding more isoprene units results in terpenes 
(C10), diterpenes (C20), triterpenes (C30), tetraterpenes (C40) and sesquiterpenes (C15). (Dewick 
2002)  
These compounds are commonly associated to plants fragrances, also known as the 
essential oils fraction. (Cowan 1999) Over the years, their biological activities have been 
highlighted, such as antimicrobial (antibacterial, antifungal, antiviral and protozoa), anti-
inflammatory effect, anti-ulcerogenic, anti-carcinogenic, hepatocellular and cardioprotective 
12 
 
effect. (Cowan 1999) The terpenes of interest in this study are triterpenes and sesquiterpene 
compounds. 
 
 
1.2.2.1 – Triterpenes 
Triterpenic compounds are constituted by six isoprene units, which can be acyclic or form 
mono-, bi-, tri-, tetra- or pentacyclic structures. (Cowan 1999) Compounds with relevant biological 
activity belong to the tetracyclic triterpenes (dammarane and euphane) and pentacyclic 
triterpenes (oleanane, ursane and lupane) classes. (Dewick 2002) Pentacyclic triterpenes have 
been widely studied, due to their various pharmacological effects, biological activities (specially 
antibacterial and antitumor) and low toxicity, which confers high potential for its use as multi-target 
therapeutic tools. (Dzubak et al. 2006; Jäger et al. 2009) These compounds are widely distributed 
and may be isolated from peel of fruits, leaves and bark of the plant stems. (Jäger et al. 2009) 
According to Jäger et al. (2009), after the screening of 39 plants, it was possible to identify 
pentacyclic triterpenes in all but their concentration was higher in the dry extracts of the following 
plants: flat trunk bark (betulinic acid), olive leaves and pomace, clove flowers and mistletoe shoots 
(oleanolic acid), any apple pulp (ursolic acid) and equal amount of the three triterpenic acids in 
rosemary leaves. (Jäger et al. 2009) 
Betulinic, betulonic, oleanolic and ursolic acids are triterpenic acids (TAs) that belong to the 
lupane (first two), oleanane and ursane family, with pentacyclic structure (Figure 1.5). 
 
 
 
 
 
 
 
Figure 1.4. Pentacyclic triterpenic acids: (1) ursolic acid; (2) oleanolic acid; (3) betulinic 
acid and (4) betulonic acid. (Adapted from Muffler, et al. (2011)) 
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These TAs have been extensively studied, mainly due to their antimicrobial activity against 
pathogenic bacteria, such as MDRB, demonstrating promising results in synergistic studies with 
conventional antibiotics. (Fontanay et al. 2008) Ursolic and oleanolic acids exhibit antibacterial 
effect mainly against Gram-positive bacteria. (Wolska et al. 2010) The minimal inhibitory 
concentrations (MIC) of oleanolic and ursolic acids against Staphylococcus spp. range from 8 to 
64 µg/mL (Fontanay et al. 2008; Gibbons 2004) and between 3 µg/mL and 64 µg/mL (Fontanay 
et al. 2008; Wang et al. 2016; Wolska et al. 2010), respectively. Moreover, when conjugated with 
antibiotics, they are capable to influence the susceptibility of multidrug-resistant S. aureus, S. 
epidermidis and L. monocytogenes to ampicillin and oxacillin. (Kurek et al. 2012) It is thought that 
the primary target of these compounds is the bacterial cell wall, causing autolysis of the cell, while 
they also may influence the bacterial gene expression responsible for formation and maintenance 
of biofilms. (Kurek et al. 2012; Wolska et al. 2010) In a study performed by Chung et al. (2011), 
betulinic acid exhibited antibacterial effect against MRSA with a MIC of 64 µg/mL. (Chung, 
Navaratnam, and Chung 2011) Furthermore, synergistic studies using betulinic acid plus 
methicillin and vancomycin individually demonstrated a decrease in bacterial growth, in both 
combinations. (Chung, Navaratnam, and Chung 2011) Lastly, betulonic acid was described as 
presenting antibacterial effect against E. faecalis and S. aureus, diminishing bacterial growth in 
74% and 51%, respectively. (Haque et al. 2014) 
 
 
1.2.2.2 – Sesquiterpenes 
Sesquiterpenes are formed from three isoprene units (C5). (Dewick 2002) Due to their long 
chain and presence of an additional double bond, the number of possible modes of cyclization 
increases, which is translated in a wide variety of mono-, bi-, and tricyclic structures. Post-
synthesis modifications may also occur, such as glycosylation and oxidation, which gives further 
diversity to the compounds. (Chadwick et al. 2013) Sesquiterpene lactones are derived from an 
oxidation reaction in the C3 of the side chain, forming a lactone. (Dewick 2002) The more 
abundant classes of sesquiterpene lactones are: germacranolides; pseudoguaianolides; 
eudesmanolides and quaianolids, being germacranolides the most important regarding biological 
activities associated to humans (Figure 1.6). 
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Figure 1.5. Sesquiterpene lactones basic structure. (Adapted from Chaturvedi (2011)) 
Sesquiterpene lactones have demonstrated benefits within human health improvement, with 
antitumor, anti-inflammatory, antibacterial, antifungal, antiviral, antiprotozoal, anthelmintics, 
antiulcer, molluscicide, hepatoprotective and antidepressant effects. (Amorim et al. 2013) In 
plants, these compounds have an important role in defense mechanisms against stress situations 
and as predator repellent. (Chadwick et al. 2013) Sesquiterpene lactones have inhibitory activity 
against Gram-positive and Gram-negative bacteria. (Chaturvedi 2011) For instance, vernodalin 
and vernolide induce higher inhibitory effect in Gram-positive (MRSA), while helenalin act 
preferably against Mycobacterium tuberculosis and Corynebacterium diptheriae, among other 
Gram-negative bacteria. (Chaturvedi 2011) Inula helenium is currently used as an antiseptic of 
the urinary tract. (Chaturvedi 2011) Cynaropicrin revealed bactericidal effect, acting as an inhibitor 
of the bacterial cell wall formation. (Bachelier, Mayer, and Klein 2006) 
Sesquiterpene lactones are present in a diverse family of plants such as Cactaceae, 
Solanaceae, Araceae, Euphorbiaceae, etc., being more abundant in Asteraceae family, the more 
diverse and abundant plants family in the world. (Chadwick et al. 2013) They are also present in 
dietary consumption of fruits and vegetables, such as lettuce and chicory, infusions and as 
additive in alcoholic drinks, conferring the bitter taste. (Chadwick et al. 2013) 
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The bioactive compounds classes with relevance to this Thesis and respective biological 
activities are summarized in Table 1.2. 
 
Table 1.2. Bioactive compounds and its biological activities. 
Bioactive compounds Biological activities 
Phenolic compounds: 
-Hydroxytyrosol 
-Tyrosol 
-Oleuropein 
Anti-allergic, antiatherogenic, anti-inflammatory, 
antitumor, antimicrobial, antioxidant, anti-
thrombotic, vasodilating and cardioprotective. 
(Balasundram, Sundram, and Samman 2006; Gurib-Fakim 
2006) 
Triterpenic acids: 
-Betulinic acid 
-Betulonic acid 
-Oleanolic acid 
-Ursolic acid 
Antimicrobial, anti-inflammatory, antiulcerogenic, 
anticarcinogenic, hepatocellular and 
cardioprotective. (Cowan 1999) 
Sesquiterpene lactone: 
-Cynaropicrin 
Antitumor, anti-inflammatory, antibacterial, 
antifungal, antiviral, antiprotozoal, anthelmintics, 
antiulcer, molluscicide, hepatoprotective and 
antidepressant. (Amorim et al. 2013) 
 
 
1.3 – Biorefinery  
Fossil fuels are used worldwide for energy and chemical production, being oil the most used. 
It is estimated that 84 million barrels of oil are used per day only in the transport sector, and this 
number tends to increase. (Cherubini 2010) Moreover, approximately 4% off the refined oil is 
widely used for chemical and plastic production. (Cherubini 2010) These processes have been 
burdening the environment, with air, water and soil pollution, causing climate changes, being 
recognized that an active intervention and paradigm shift is required. (Fernando et al. 2006) 
Therefore, the search for alternatives to fossil fuels is mandatory but still a huge challenge. The 
recycling concept is well established in the society, and thus, it can be extended to industries, that 
while using raw materials of plant origin, generate large amounts of waste (biomass), which can 
be further reused. (Fernando et al. 2006) In this context, the biorefinery concept has emerged, 
being defined as the sustainable processing of biomass in a marketable products spectrum and 
energy. (Fernando et al. 2006) Thus, a biorefinery should consist in a unit (or several) 
incorporating the equipment and technology required for biomass processing considered as 
waste (wood, grass, corn, etc.) and its basic components (carbohydrates, proteins, triglycerides, 
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etc.) into biofuel, electricity and chemicals, in the concept of exhausting its resources completely 
(Figure 1.7). (Cherubini 2010) 
The "power supply" of biorefineries consist in raw carbon-derived materials, supplied from 
four main sectors: agriculture (crop and waste fields), forestry industries (waste and leftovers 
processes), housing (solid waste and municipal wastewater) and aquaculture (algae). (Cherubini 
2010) 
 
 
Figure 1.6. Biorefinery concept. (Herrera 2004) 
 
In the present Thesis three biomasses, and respective extracts, from different sources, were 
used: 1) forestry – Eucalyptus spp. total bark, from pulp and paper industry; 2) agriculture – olive 
pomace, from olive oil production and; 3) Cynara cardunculus (cardoon), as an endogenous 
resource from the Alentejo region, mainly used in artisanal cheese production. 
 
1.3.1 – Eucalyptus spp. and paper production  
Eucalyptus spp. is the main raw material used for pulp and paper production in the paper 
industry, an economical sector with high economical relevance in the Iberian Peninsula. 
(Domingues et al. 2010) Eucalyptus urograndis, E. grandis, E. maidenii, E. globulus and E. nitens 
are the main species (Figure 1.8a). (Domingues et al. 2010)  
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Figure 1.7. Eucalyptus spp. in Portugal: a – Geographic distribution of Eucalyptus spp. in 
Portugal; b – Relationship between evolution of Eucalyptus spp. area and the Eucalyptus 
spp. pulp production, reaching 812 000 ha in 2010. (Adapted from: Source CELPA and 
ICNF, I.P.) 
This industry generates large quantities of sub-products, approximately 1.0 x 105 ton/year, 
such as bark and wood waste (leaves, branches, fruits, etc.), which are usually left in the forest 
to nourish the soil or are burned for energy. (Domingues et al. 2011; Domingues et al. 2012) It is 
an industry that is constantly increasing its production levels (Figure 1.8b) and, therefore, the 
implementation of the biorefinery concept would allow to completely reuse the waste (biomass), 
as well as to increase the economical potential of the sector.(Domingues et al. 2011) 
The main compounds found in this biomass are phytosterols, such as β-sitosterol, lignans 
and botulin.(Domingues et al. 2010) It is described in the literature that the outer bark of 
Eucalyptus spp. is the richer fraction in triterpene compounds, as well as monoterpenes and 
sesquiterpenes, small amounts of fatty acids and aromatic compounds. (Domingues et al. 2010) 
The main TAs present in Eucalyptus spp. are the ursolic, oleanolic, betulinic, betulonic, 3-
acetylursolic and 3-acetyloleanolic acids. (Domingues et al. 2010) According to Pereira et al. 
(2014) studies, E. globulus-derived extracts showed promising results in antimicrobial activity, 
either isolated or in combination with conventional antibiotics. (Pereira et al. 2014) 
 
 
 
 
 
a b 
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1.3.2 – Olive and olive oil production  
Olive trees (Olea europaea L.) are native from the Mediterranean region, but during the last 
decade, its cultivation worldwide has increased, due to the recognized benefits of olive oil 
consumption in human health (Figure 1.9a). (Romero-García et al. 2014) In 2013, 2.67 million 
tons of olive oil were produced for human consumption in Europe. (Romero-García et al. 2014) 
In addition to oil, olives are also a product of interest for consumption. (Romero-García et al. 
2014) In Portugal, between 2000 and 2009, olive oil production increased approximately 63%, 
especially in the Alentejo region, representing 56% of the total national production. (Ramos et al. 
2013) In 2013, 999 853 hectoliters of olive oil were produced, having 689 261 hectoliters been 
produced in the Alentejo region (Figure 1.9b). (Instituto Nacional de Estatísitca (INE) 2014) 
 
 
 
 
Figure 1.8. Olive tree in Portugal: a – Geographic distribution of olive trees in Portugal. 
(Adapted from: source INE, RA 2009) b – Olive oil production, between 2009 and 2013, 
reached an approximated average value of 800 000 hl. (Adapted from: source INE, EA 
2013) 
In Alentejo, olive oil extraction is made through a centrifugation system in two phases, which 
generates a large amount of a residue named olive pomace, with high water content and 
composed mainly of skin, pulp and stone pieces of olive fruit. (Ramos et al. 2013) Every year, it 
is estimated that 400 000 ton of this residue are generated, which is subsequently subjected to 
drying at high temperatures, resulting in another residue, dry olive pomace that is mainly used for 
energy production (combustion). (Ramos et al. 2013) Phenolic compounds can be extracted from 
both residues. (Ramos et al. 2013) According to Ramos et al. (2013), dry olive pomace revealed 
a b 
19 
 
higher phenolic content than olive pomace, being hydroxytyrosol the more abundant. (Ramos et 
al. 2013) Other phenolic compounds were identified in dry olive pomace extract, namely HT-1-
glucoside, tyrosol, oleuropein aglycone isomers, verbascoside, oleuropein and 
de(carboxymethyl)oleuropein aglycone isomer in aldehyde form. (Ramos et al. 2013) 
 
 
 
1.3.3 – Cynara cardunculus – artisanal cheese production and other applications 
Cynara cardunculus (cardoon) can be found in the Mediterranean region and its distribution 
in Portugal is represented in Figure 1.10.  
 
 
Figure 1.9. Geographic distribution of Cynara carcunculus in Portugal. (Marabuto et al. 
2016) 
C. cardunculus is divided in three taxa: two domestic forms, the artichoke (var. scolymus L.) 
and cultivated cardoon (var. altilis), and wild cardoon (var. sylvestris) (Figure 1.11). 
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Figure 1.10. Morphological appearance of each variant of Cynara cardunculus: (a) var. 
sylvestris , (b), var. scolymus L.  and  (c) var. altilis. (Source: CEBAL) 
It has rigorous growth conditions, demanding high temperatures, high salinity and low 
precipitation. (Falleh et al. 2008) C. cardunculus is associated to a wide variety of applications, 
such as in the Mediterranean diet in Spain, Italy, France and south of Portugal; in artisanal cheese 
production and in pulp industry. (Falleh et al. 2008; Velez et al. 2012) Recently, it has shown 
promising results for biodiesel production. (Velez et al. 2012) The valorization of C. cardunculus 
is mainly linked to the lignocellulosic fraction and the high value compounds that constitute it. 
(Ramos et al. 2013) The major compounds have been identified by Ramos et al. (2013), being 
among them a sesquiterpene lactone (diacylcynaropicrin), four pentacyclic triterpenes (β- and α-
amyrin, lupenyl and ψ- taraxasteryl acetate) and four sterols (stigmasterol, 24-
methylenecholesterol, campesterol and Δ5-avenasterol). (Ramos et al. 2013) Cynaropicrin and 
ψ- taraxasteryl acetate are the sesquiterpene lactone and pentacyclic triterpene, respectively, 
found in higher concentrations. (Ramos et al. 2013) These compounds are responsible for the C. 
cardunculus pharmacological effects, which has led to an increase in its cultivation and biological 
activity studies. (Velez et al. 2012) 
 
 
1.4 – Pharmaceutical formulation 
1.4.1 – Formulation Design 
Drugs are usually included in formulated preparations, varying in complexity according to the 
type and amount of excipients/additives added. (Aulton 2002) These vehicles provide different 
characteristics to formulations, depending on the final preparation or dosage form desired, such 
as solubility, thickness, preservation, emulsion, among others. (Aulton 2002) 
There is a large variety of dosage forms where the drug can be incorporated, generally 
chosen according to the more convenient and best administration route and also in order to obtain 
maximum effectiveness and, consequently, have the maximum therapeutic response. (Aulton 
2002) Various administration routes and associated dosage forms are shown in Table 1.3. 
  
a b c 
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Table 1.3. Administration routes and dosage forms associated. (Aulton 2002) 
Administration route Dosage forms 
Oral 
Solutions, syrups, suspensions, emulsions, 
gels, powders, granules, capsules, tablets 
Rectal 
Suppositories, ointments, creams, powders, 
solutions 
Topical 
Ointments, creams, pastes, lotions, gels, 
solutions, topical aerosols 
Parenteral 
Injections (solution, suspension, emulsion 
forms), implants, irrigation and dialysis 
solutions 
Respiratory 
Aerosols (solution, suspension, emulsion, 
powder forms) - sprays; foams 
Nasal 
 
Solutions, inhalators 
Eye 
 
Solutions, ointments, creams 
Ear 
 
Solutions, suspensions, ointments, creams 
 
Among these dosage forms, solutions for topical administration are those with relevance for 
this Thesis. According to pharmaceutical terms, solutions are liquid preparations that contain one 
or more chemical substances dissolved in a suitable solvent or mixture of mutually miscible 
solvents. (Ansel, Popovich, and Allen 1989) Generally, topical solutions are formulated in an 
aqueous vehicle and it is necessary the addition of co-solvents, among other excipients, to 
enhance both stability and solubility of the drug. (Ansel, Popovich, and Allen 1989) Liquid dosage 
forms, as topical solutions, are mainly used for local application and present several advantages, 
such as ease of administration and faster absorption, since the drug is already dissolved and, 
therefore, it is easily available for skin absorption. However, solutions can also present 
disadvantages, such as: the lower chemical stability of the formulation components, as they are 
more susceptible to hydrolysis; as well as the fact that this may be a suitable medium for 
microorganisms proliferation. (York 2000) 
 
In a technical way, a pharmaceutical formulation can be defined as the set of operations that 
aims to create a physical system which contains the active substance in order to meet the 
specifications of the formulation and ensure the maintenance of efficacy and safety of the active 
substance (Figure 1.12). (Sousa e Silva 2013) 
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Figure 1.11. Representative scheme of main stages of formulation design.(Sousa e Silva 
2013) 
 
This process is performed in order to select, optimize and evaluate the pharmaceutical 
preparations obtained. (Sousa e Silva 2013) The final product must be stable, efficacious, well-
conditioned, attractive, easy to administer, and safe. (Allen 2010) 
 
1.4.2 – Quality control and stability study 
The stability of pharmaceutical formulations is defined as the ability of a formulation, 
appropriately packed, to maintain the physical, chemical, microbiological, therapeutic and 
toxicological characteristics in compliance with its specifications. Environmental conditions such 
as heat, light and humidity and chemical factors, such as oxidation, reduction, hydrolysis, among 
others, may play a very important role in stability. 
There are official guidelines for quality control that must be followed in order to ensure that 
pharmaceutical formulations maintain their quality, effectiveness and safety. This quality standard 
is periodically published in pharmacopeias of major pharmaceutical manufacturing and exporting 
countries. The U.S. Pharmacopeia, European Pharmacopoeia, International Pharmacopoeia, 
published by the WHO, and the British Pharmacopoeia are widely used. (WHO 2012) 
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The main characteristics that should be well established and controlled in a formulation are: 
identity, purity, drug assay, uniformity of dosage form, and stability (Table 1.4). These 
characteristics can be affected cumulatively through the several steps of the manufacturing 
process, including the starting materials, errors in manufacturing process, packaging, 
transportation and storage conditions. (WHO 2012) 
 
Table 1.4. Examples of quality control parameters of a pharmaceutical formulation. (WHO 
2012) 
Quality Control Description 
Identity 
The identity test should confirm the presence of the 
active substance. 
Purity 
The ingredients used should not have potentially 
harmful contaminants, microorganisms or other 
products from cross-contamination. 
Drug assay 
The pharmaceutical formulation should contain the 
declared amount of the active substance. Most 
pharmacopoeias specify an average content range 
of active substance as well as of by-products of 
degradation that may be harmful. 
Uniformity of dosage forms 
Consistency, color, shape and size of certain 
formulation forms should not vary between doses. 
The lack of uniformity may suggest problems in 
other quality parameters, and reflect a lack of good 
manufacturing practices. 
Stability 
Stability studies allow obtaining information of better 
conservation conditions and predicting expiration 
date. They are performed under normal storage 
conditions, called real-time assays, where physical, 
chemical and microbiological parameters are 
evaluated over time. 
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2 – Objectives 
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The main objective of this work was to establish the foundations for the design of a novel 
antiseptic formulation, based on natural extracts obtained from forest/agriculture industry by-
products, against multi-drug resistant bacteria (MDRB). Three biomasses, Eucalyptus spp., dry 
olive pomace and Cynara cardunculus, described in the Introduction section, were tested and the 
experimental work was based on four main tasks:  
 
 Task 1 – The antibacterial activity of industry by-products (in the form of extracts), namely 
of E. nitens total bark, dry olive pomace and C. cardunculus leaf -derived extracts, was 
tested against MDRB, in order to define the best one(s) to be included in the formulation 
design. For that, minimal inhibitory concentrations (MIC) and minimal bactericidal 
concentration (MBC) were determined.  
 Task 2 – Time-kill assays: the antibacterial efficiency of the selected biomass(es) 
extract(s) in decreasing the microbial load over time was studied. Possible synergistic 
interactions between the extracts and standard antibiotics were also evaluated; 
 Task 3 – Formulation design: various solvents and excipients were tested in order to 
define the best matrix for dissolving the selected bioactive(s). After achieving the desired 
formulation, physico-chemical and organoleptic characterizations were performed. 
Quality control, regarding alterations in the formulation over time, was executed; 
 Task 4 – In vitro assays of the designed formulation(s), to infer the antibacterial activity 
of the designed formulation against a panel of MDRB.   
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3 – Material & Methods 
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3.1 – Plant material and extraction method 
3.1.1 – Eucalyptus spp. 
E. nitens total bark lipophilic fraction extract (E. nitens total bark (ENTB) extract) was 
produced at CICECO/University of Aveiro, Aveiro, Portugal, in the framework of the project 
“NEucBark – New Valorization Strategies for Eucalyptus spp. Bark Extracts” (PTDC/AGR-
FOR/3187/2012). 
Extraction was performed in accordance to Domingues et al. (2011). Briefly, Soxhlet method 
was used with dichloromethane as extraction solvent, since it is fairly specific for lipophilic 
extractives. Afterwards, solvent was evaporated, dry biomass weighed and results were 
expressed in percentage of dry bark. The final extract was kept at -20°C until further use.  
(Domingues et al. 2011) 
 
3.1.2 – C. cardunculus 
C. cardunculus L. var. altilis leaves were collected by CEBAL in Experimental Center of 
Agriculture School of the Instituto Politécnico de Beja, Portugal, in the framework of the project 
“ValBioTecCynara – Economic valorization of Cardoon (Cynara cardunculus): study of natural 
variability and biotechnological applications” (ALT20-03-0145-FEDER-000038). 
The C. cardunculus leaves (CcL) lipophilic fraction extraction was performed according to 
Ramos et al. (2013) Leaves, as the other collected samples, were freeze-dried before extraction. 
Soxhlet extraction method was used with dichloromethane as solvent of extraction. In the end, 
solvent was evaporated to dryness at low pressure and the extract weighted, being the results 
expressed as percentage of dry biomass material. Dichloromethane was used as extraction 
solvent due to its specificity for lipophilic extractives.(Ramos et al. 2013) The extract was kept at 
RT and protected from light until further use. 
 
3.1.3 – Dry olive pomace  
Dry olive pomace (DOP) was provided by Mariano Lopes & Filhos, Lda. (União de 
Cooperativas Agrícolas do Sul - UCASUL), in the framework of the project “RefinOlea – An 
integrated valorization strategy for by-products of olive oil extraction industry” (FCOMP-01-0202-
FEDER-005450), being kept at RT until further use. 
 
 
3.1.3.1 – DOP phenolic extraction 
The extraction protocol was performed according to Ramos et al. (2013). Briefly, about 8 g of 
DOP were mixed with 120 mL of distilled water under constant stirring, protected from light, at 
RT, for 40 min. The mixture was then centrifuged at 9 000 x g, for 10 min, at RT (Centrifuge 
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Hermle Z323K, Hermle Labor Technik). The supernatant was collected and protected from light; 
while the leftover solid residue was extracted five times more. The extraction conditions were 
similar, except for the stirring time, which was successively shorter (30, 15, 10 and 2x 5 min). All 
the collected supernatants were filtered through a 0.22 µm PES filter (Pall Life Sciences). Finally, 
water was removed by freeze-drying (Coolsafe TM, Scanvac) and solid extracts were kept at 
−20°C, protected from light, until further analysis. (Ramos et al. 2013) 
 
3.1.3.1.1 – Determination of total phenolic content 
The quantification of total phenolic content was performed using Folin-Ciocalteau method, 
according to Falleh et al.(2008). Briefly, in a 96-well plate, 10 µL of extract were added at a 
concentration of 1mg/mL (extract dissolved in distilled water) and 150 µL of Folin-Ciocalteau 
reagent 10% (v/v). The plate was vortexed and kept in the dark for 5 min, at RT. Subsequently, 
150 µL of sodium carbonate solution 60 g/L were added, the plate vortexed and kept in the dark 
for 60 min. Finally, optical density (OD) was read against a blank composed by distilled water, 
instead of extract, in a plate reader (Multiskan FC, Thermo Scientific) at λ= 750 nm. A calibration 
curve was performed, using Gallic acid as standard phenolic compound, in a concentration range 
of 0.04 – 0.250 mg/mL. Triplicates for each extract sample and standard concentration were 
made. 
 
3.1.3.1.2 – Quantification of hydroxytyrosol, tyrosol and oleuropein by high-performance liquid 
chromatography-UV/Vis (HPLC-UV/Vis) 
Quantification of the phenolic compounds hydroxytyrosol, tyrosol and oleuropein were 
performed with a Merck Hitachi HPLC system (Tokyo, Japan). A LiChrospher® RP-18 column 
5µm particle size (Merk Millipore) was used at 30°C, with a flow rate of 1.5 mL/min and a gradient 
elution. The mobile phases consisted in water (HPLC grade) with 0.5% of acetic acid (Sigma-
Aldrich) (A) and acetonitrile (Fisher Scientific) (B). The following multistep linear gradient (% v/v) 
was applied: 0 min, 5%B; 10 min, 30%B; 12 min, 33%B; 17 min, 38%B; 20 min, 50%B; 23 min, 
95%B, 27 min, 5%B until the end of the run (37 min). The injection volume of the sample was 5 
µL and the UV/Vis detection was performed at λ= 280 nm. Before HPLC injection, extract samples 
were dissolved in water (HPLC grade) and then filtered through a 0.22 µm syringe filter (VWR). 
Calibration curves were constructed using standard solutions of each phenolic compound, using 
the following concentrations: hydroxytyrosol 50, 100, 200, 300, 500 µg/mL; tyrosol 50, 75, 150, 
300, 500 µg/mL; oleuropein 50, 100, 200, 300, 450, 600 µg/mL. 
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3.2 – Bacterial strains and growth 
A panel of MDRB was used (Table 3.1). These bacteria were chosen for being the main 
players in NI. 
Table 3.1. MDRB panel used.  
Bacteria 
G
ra
m
-n
e
g
a
ti
v
e
 
Escherichia coli ATCC 25922 
Escherichia coli OXA 
Escherichia coli TEM 180 
Klebsiella pneumoniae* 
Citrobacter freundii* 
Salmonella enterica* 
Pseudomonas aeruginosa PAOI 
G
ra
m
-p
o
s
it
iv
e
 Staphylococcus saprophyticus* 
Staphylococcus epidermidis* 
Staphylococcus aureus ATCC 43300 
Staphylococcus aureus ATCC 6538 
 
* clinical isolates  
 
Bacterial cultures were kept at -80°C in freezing medium, composed of Brucella broth (Fluka 
Analytical) with 20% (v/v) of glycerol (Liofilchem)). To start the cultures, bacteria were defrosted 
at RT, being afterwards incubated in Muller Hinton Broth (MHB, Liofilchem), with agitation (200 
rpm) in an orbital shaker (SI-300/300R/600/600R, Lab companion), at 37°C, for 6 hours. After 
incubation, cultures were plated in Mueller Hinton Agar (MHA, Liofilchem) and Tryptic Soy Agar 
(TSA, Liofilchem), using the quadrant streak method. Plates were incubated overnight at 37°C. 
All bacterial assays were performed in a sterile environment, in a biosafety level 2 laminar 
flow chamber (TOPSAFE 1.2, EuroClone). 
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3.3 – Antibacterial activity assays 
3.3.1 – Antibiotics antibacterial activity assay 
In this study, 4 antibiotics were used: tetracycline (Duchefa Biochemie, Alfagene), ampicillin 
(Applichem, VWR), rifampicin (Duchefa Biochemie, Alfagene) and gentamicin (Duchefa 
Biochemie, Alfagene) as representative of broad-spectrum antibiotics. 
 
3.3.1.1 – Minimal inhibitory concentrations (MIC)  
MIC is defined as the minimum concentration of antibacterial agent that can inhibit visible 
bacterial growth and is mostly used to test bacterial susceptibility to antibacterial agents. 
(Wiegand, Hilpert, and Hancock 2008) MICs were determined by the microbroth dilution method 
as described elsewhere with small changes (Figure 3.1). (Wiegand, Hilpert, and Hancock 2008)  
 
Figure 3.1. Microbroth dilution method. 
 
In this method, a defined number of bacterial cells are incubated with the antimicrobial agent 
in test in a defined concentration range, by performing 1:2 serial dilutions. After the incubation 
period, bacterial growth, if occurring, is visible to the naked eye through turbidity of solution. 
However, in this study, both qualitative and quantitative methods were required to improve the 
results assessment, since the tested extracts added turbidity to the solution per se. Therefore, a 
qualitative method (MTT assay) was performed, in order to be possible to observe results with 
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naked eye. To add further precision to the assay, OD measurements (λ= 600 nm) were performed 
(quantitative method).  
Assays were performed with bacterial cultures grown in MHA plates. Cultures were harvested 
from the plates with 1 mL of MHB medium, centrifuged twice at 2700 rpm, for 5 min. OD was 
determined at λ= 600 nm and adjusted to 0.04 (approximately 105 cfu/mL, previously determined 
by our group) in MHB medium. Bacterial incubation was done at 37ºC, 200 rpm, until exponential 
growth phase was reached and then, the OD was again adjusted to 0.04. In 96-well plates 
(Sarstedt), serial dilutions of the antibiotics were added to the previously calibrated inoculum (105 
cfu/mL), starting with the highest concentration (2048 µg/mL) and performing serial dilutions until 
8 µg/mL (Figure 3.1). Growth control (GC), sterility control (StC) and solvent control (SC) were 
also prepared: GC, the positive control, ensures that bacterial growth is occurring, being used to 
compare with bacterial growth in the presence of the antibiotics; StC, the negative control, allows 
to exclude contaminations in the assay; SC is used to assess if the solvent, at the maximum 
percentage used in the assay, influences bacterial growth. Plates were sealed with parafilm to 
avoid evaporation during overnight incubation (~16h) at 37°C. After, MICs were determined 
qualitatively through (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay 
and quantitatively by OD measurement (λ= 600 nm) (Multiskan FC, Thermo Scientific).  
MTT (Merck) is widely used to test cell metabolic activity. Metabolically active cells react with 
MTT, resulting in a purple colored formazam product that can be observed with unaided eye.(Riss, 
Niles, and Minor 2004)  
The MIC determination protocol with MTT was designed and performed based on Eloff 
(1998). Shortly, an MTT stock solution, in a concentration of 0.2 mg/mL in BPW, sterilized with a 
0.22 µm filter (VWR), was kept at -20ºC. For each assay, the stock solution was defrosted at RT 
and, afterwards, 40µL of the MTT solution were added to the each well in the 96-well plate. 
Incubation was done at 37ºC, 40 min. Assays were performed in triplicate and in three 
independent experiments. The lowest concentration where did not occur color change, in the 
three wells (triplicates of the assay), where defined as MIC of the antibacterial agent in test, in 
this case of the antibiotics. 
 
3.3.2 – TAs and ENTB extract for antibacterial activity assays 
For antibacterial activity assays, betulinic acid (BA) (Molekula), betulonic acid (BOA) 
(CHEMOS GmbH), oleanolic acid (OA) (Molekula) and ursolic acid (UA) (Molekula), were used 
as pure compounds, representative of the main TAs found on the ENTB extract composition.  
TAs and ENTB extract stock solutions, 50 mg/mL, were prepared in absolute ethanol (99.8%; 
VWR Prolab), aliquoted and kept at -20°C. Before use, TAs and ENTB stock solutions were 
defrosted at RT. MICs were determined using the same procedure as previously described for 
antibiotics antibacterial activity assay (3.3.1.1). 
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3.3.2.1 – Minimal bactericidal concentration (MBC) determination 
MBC is defined as the lowest concentration of antimicrobial agent required to kill 99.9% of 
the final inoculum after incubation for 24 h. (Balouiri, Sadiki, and Ibnsouda 2016) MBCs were 
determined using the spreading technique in MHA plates. MICs, previously determined, were 
serially diluted (10-1 to 10-4) in buffered peptone water (BPW; Liofilchem) and 10 µL of each, as 
well as a non-diluted MIC (100), were plated. MHA plates were incubated at 37°C, for 24 hours, 
being observed afterwards if there was bacterial growth. If bacterial growth occurred, then the 
number of colony forming units (CFUs) was determined. MBC was subjectively defined as the 
lowest concentration, at which 99.9% of the final inoculum were killed. 
 
 
3.3.2.2 – Time-kill assay 
Time-kill assay is used to observe the evolution of the inhibitory/bactericidal effect of an 
antimicrobial agent over time, being based on the MIC determination (3.3.1.1). For each 
incubation time, a 96-well plate was prepared corresponding to the different incubation times (2h, 
6h, 24h and 48h). The MIC was qualitatively determined through MTT assay (3.3.1.1) and 
quantitatively by OD measurement at λ= 600 nm. 
 
3.3.2.3 – Synergistic assays (ENTB extract plus antibiotics) 
In this study, four antibiotics were used: tetracycline (Duchefa Biochemie, Alfagene), 
ampicillin (Applichem, VWR), rifampicin (Duchefa Biochemie, Alfagene) and gentamicin (Duchefa 
Biochemie, Alfagene) together with ENTB extract. Microbroth dilution method was used (3.3.1.1) 
in a concentration range of 2 µg/mL up to 2048 µg/mL. GC and StC were also prepared. Results 
were obtained through MTT assay (3.3.1.1) and by OD measurement at λ= 600 nm on a plate 
reader (Multiskan FC, Thermo Scientific). Factorial inhibitory concentration index (FICI) was 
calculated to classify interaction between ENTB extract and antibiotics.(Pereira et al. 2014) Each 
of the combinations was calculated according to the following equation (Equation 1): 
 
𝐹𝐼𝐶𝐼 =  
𝑀𝐼𝐶 (𝐴𝑛𝑡𝑖𝑏𝑖𝑜𝑡𝑖𝑐+𝐸𝑁𝑇𝐵 𝑒𝑥𝑡𝑟𝑎𝑐𝑡) 
𝑀𝐼𝐶 (𝐴𝑛𝑡𝑖𝑏𝑖𝑜𝑡𝑖𝑐)
 (1) 
 
Results were interpreted as follows: FICI ≤ 0.5 synergistic, 0.5 < FICI < 1 partially synergistic, 
FICI = 1 additive, 1 < FICI ≤ 4 indifferent and FICI > 4 antagonistic. 
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3.3.3 – CcL extract antibacterial activity assay 
For the antibacterial activity assay, the pure compound cynaropicrin (Extrassynthese) was 
used as control of the main bioactive compound found in CcL extract.  
Stock solutions of cynaropicrin and CcL extract were prepared at a concentration of 50mg/mL 
in DMSO (99.5%, AppliChem), aliquoted and kept at -20°C. MICs were determined using the 
same procedure as previously described for antibiotics antibacterial activity assay (3.3.1.1). 
 
3.3.4 – DOP extract antibacterial activity assay 
For DOP extract antibacterial activity assay, pure compounds of phenolic compounds 
hydroxytyrosol (H), tyrosol (T) and oleuropein (O) (Sigma-Aldrich) were used as controls of the 
main bioactive compounds detected in DOP extract.  
Stock solutions of phenolic compounds and DOP extract were prepared at a concentration of 
50 mg/mL in absolute ethanol (99.8%; VWR Prolab). Aliquots were kept at -20°C. MICs were 
determined as previously described (3.3.1.1). 
 
3.4 – Quantification of reducing sugars content  
3.4.1 – ENTB extract 
Reducing sugars were determined by the 3,5-dinitrosalicylic (DNS) colorimetric method, 
according to Miller (1959). Briefly, when the DNS alkaline solution reacts with reducing sugars, it 
is converted into 3-amino-5-nitrosalicylic acid (orange color), being the OD of the solutions 
measured at λ= 540 nm.  
The reaction mixture was composed of 500 µL of ENTB extract, 50 mg/mL in absolute ethanol 
(99.8%; VWR chemicals) and 3 mL of DNS reagent. The mixture was homogenized in a vortex 
(Velp Scientific) and incubated for 5 min, at 100°C in a thermic bath (WND29, Memmert). After 
cooling in ice, 15 mL of distilled water were added and again left to cool at RT for 15 minutes. The 
supernatant absorbance was measured at λ=540 nm (Helios Alpha, Thermo Scientific), against a 
blank composed of water and DNS reagent. Calibration curves were done using standard 
solutions of xylose and glycose, with concentrations between 1 - 8 mg/mL, following the same 
procedure previously described. Triplicates for each extract sample and standard concentration 
were performed. 
 
3.4.2 – CcL extract 
Concentrations of reducing sugars were determined as described for ENTB extract (3.4.1) 
CcL extract was dissolved in DMSO (99.5%, AppliChem) to a final concentration of 50 mg/mL. 
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3.4.3 – DOP extract 
Reducing sugars concentration was determined as previously described for ENTB extract 
(3.4.1). DOP extract was dissolved in distilled water to a final concentration of 50 mg/mL. 
 
 
3.5 – Formulation 
3.5.1 – Formulation design 
Formulations design and characterization were performed at Faculdade de Farmácia of 
Universidade de Lisboa (FFUL), Lisboa, Portugal. Further adjustments in the formulation 
composition were executed at CEBAL, according to the obtained antimicrobial activity results.  
Preformulation tests started by dissolving one of the extracts, the ENTB extract, in absolute 
ethanol (99.8%, VWR Prolab), and then different excipients were added under stirring, in order to 
confer physical stability to the formulation. The excipients tested were: Emulcin (Bial), propylene 
glycol (Merck) and TAGATCH40 (Evonik). Ascorbic acid was added to prevent oxidation and 
potassium sorbate as a preservative (Table 3.2). Finally, purified water obtained by reverse 
osmosis (Millipore, Elix 3) was added Qs 100%. 
After preparation, the solution was stored in dark flasks at 4ºC.  
 
Table 3.2. Ingredients of the initial formulation. 
Ingredients Concentration (% w/w) 
ENTB extract 0.1 
Ethanol 4 
TAGATCH40 5 
Ascorbic acid 0.2 
Potassium sorbate 0.1 
Purified water Qs 100 
 
 
3.5.2 – Formulation characterization  
Formulation characterization was assessed in different parameters. Stability tests were 
performed at both RT (approximately 25°C) and 4°C. The more relevant parameters were 
evaluated at predetermined time points. 
 
3.5.2.1 – Organoleptic characteristics 
The operator performed macroscopic appearance and sensorial analysis. 
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3.5.2.2 – Identification and quantification of the active substances  
TAs quantification (BA, BOA, UA and OA) was performed with a Dionex UHPLC UltiMate 
3000 system. A LiChrospher® RP-18 column 5 µm particle size (Merk Millipore) was used at 20°C 
with a flow rate of 1 mL/min using an isocratic elution. The mobile phase was composed 20% by 
water (HPLC grade): 80% acetonitrile (%v/v) (Fisher Scientific, HPLC grade). The injection 
volume of the sample was 50 µL and the UV/Vis detection was performed at λ= 204 nm. 
Calibration curves were obtained using TAs standard solutions, between 0.2 and 1 mg/mL. 
According to the results obtained (4.4.1.1), the quantification was performed in Formulation C 
(0% of TAGATCH40) samples containing higher concentration (0.7%) than those in formulation 
(0.1%), due to the equipment limit of detection.  
 
3.5.2.3 – pH determination 
The formulation pH was evaluated by potentiometry (Metrohm pH Meter 744 with a glass 
electrode; Herisau, Switzerland). 
 
3.5.2.4 – Rheology 
The rheology study was performed using a controlled shear-strain rheometer (Malvern 
Kinexus lab+, England) connected to a refrigeration circuit with controlled temperature. Flow 
curves were generated by ramping the controlled shear rate from 10 and 200 s-1. All tests were 
carried out on, approximately, 5 mL samples, at 20ºC using a 2°/60 mm cone.(Dias et al. 2016) 
Determinations were done in triplicates. The obtained flow curves were evaluated according to 
Newton’s Law (Equation 2): 
 
𝜏 =  𝜇 × 𝛾͘       (2) 
 
Were 𝜏 refers to shear stress (Pa), 𝜇 refers to dynamic viscosity (Pa.s) and 𝛾͘ shear rate (s-1). 
 
3.5.2.5 – Microbiological assay  
The microbiological assay was performed through the spread plate technique. Briefly, 10 µL 
of serial dilutions of the formulation (10-1 to 10-4), as well as a non-diluted sample (100), were 
plated in TSA plates. Plates were incubated at 37°C for 24h, being the results observed 
afterwards. 
3.5.3 – Antimicrobial activity of the formulations 
The antimicrobial activity of the formulation(s) was evaluated according to the microbroth 
dilution method, previously described (3.3.1.1), using a formulation % range from 5.6 % up to 90 
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%. SC, GC and StC were also performed. Results were determined through OD measurement, 
at λ= 600 nm, on a plate reader (Multiskan FC, Thermo Scientific). 
 
 
3.6 – Statistical analysis 
All parameters measured were performed at least in duplicate and analyzed using the PROC 
GLM option of SAS (SAS Institute Inc., Cary, NC, USA). Values of p < 0.05 were considered 
statistically significant. Least square means and standard deviation are presented in tables, 
except for ENTB and CcL extracts antibacterial effect, which least square means and standard 
deviations are presented in figures (Figure 4.2 and Figure 4.5).  
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4 – Results & Discussion 
  
40 
 
4.1 – Plant material extraction 
DOP extraction was performed in triplicate, being the total phenolic content in the extract 
determined for each replica. Gallic acid was used as standard and results are expressed as 
milligram of Gallic acid per gram of dry weight of extract and biomass (mg GAE/g DW). Results 
concerning the extraction yield and the total phenolic content, in extract and biomass, are 
presented in Table 4.1.  
 
Table 4.1. DOP extraction yield (%) and total phenolic content expressed as 
milligrams of Gallic acid (GAE) equivalents per gram of dry weight (DW). Values 
are expressed as mean ± standard deviation of triplicates. 
 
 Total phenolic content (mg GAE/g DW) 
Extraction yield (%) Extract Biomass 
17.32 ± 3.04 87.91 ± 7.74 17.55 ± 2.06 
 
In comparison to the results obtained by Ramos et al. (2013), the present extraction yield was 
1.62 times lower. However, the total phenolic content in the present extraction was similar, as 
expected. (Ramos et al. 2013) 
Phenolic content in hydroxytyrosol, tyrosol and oleuropein, the ones of interest in the present 
work, was determined for each extract replica and in threefold. This quantification was performed 
to determine if the quantities of hydroxytyrosol, tyrosol and oleuropein present in the extract are 
sufficient to confer significant anti-MDRB activity to the extract. Results are presented in Table 
4.2. 
 
Table 4.2. Extract phenolic content in hydroxytyrosol, tyrosol and oleuropein 
(DW) and its respective retention times. Values are expressed as the mean ± 
standard deviation of triplicates 
 
 
Phenolic content (mg/g DW) 
Retention time (min) 
Extract Biomass 
Hydroxytyrosol 25.39 ± 1.08  6.93 ± 0.81  5.62 
Tyrosol 1.93 ± 0.28 0.60 ± 0.06 6.87 
Oleuropein 3.35 ± 0.28  0.58 ± 0.11  10.61 
 
DOP extract presented higher content in hydroxytyrosol, followed by tyrosol and oleuropein. 
These phenolic compounds represent 24.11, 1.83 and 2.23 %, respectively, of the total phenolic 
content in DOP extract; and 43.59, 3.80 and 3.68 %, respectively in biomass.  
In the present work, hydroxytyrosol, tyrosol and oleuropein concentrations are similar to those 
reported by Ramos et al. (2013), both in extract and biomass, as expected, since the same 
methodology was applied.  
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4.2 – Antibacterial activity assays 
4.2.1 – Antibiotics 
The antibiotics MICs were determined by microbroth dilution method, in a concentration range 
between 8 and 2048 µg/mL. Microbroth dilution method was chosen because it is more accurate 
and easier to perform than other methods described for antibacterial activity assays, such as agar 
dilution and macrobroth dilution methods. (Balouiri, Sadiki, and Ibnsouda 2016) In agar dilution 
method, an impregnated disc with the antibacterial agent is used, being then the agent diffused 
to the media, where bacteria were previously plated and, after incubation, the diameter of the 
inhibition halo is measured in mm. (Balouiri, Sadiki, and Ibnsouda 2016) This method is simple 
and cheap, however it is not the most accurate for MICs determination, since it is not possible to 
quantify the amount of the antimicrobial agent diffused into the agar medium. (Balouiri, Sadiki, 
and Ibnsouda 2016) The main advantages of microbroth dilution compared to the macrobroth 
dilution method are the lower volumes of antibacterial agents and reagents required to perform 
the assay, as well as the higher reproducibility and the possibility to perform several replicates or 
test more than one antibacterial agent at the same time, making this method easier to perform, 
economical and less time consuming. (Balouiri, Sadiki, and Ibnsouda 2016)  
MICs for gentamicin, rifampicin, ampicillin and tetracycline against MDRB are presented in 
Table 4.3.  
 
Table 4.3. MIC of antibiotics against MDRB 
 MIC (µg/mL) 
Bacteria Gentamicin Rifampicin Ampicillin  Tetracycline 
Escherichia coli ATCC 25922 < 8 32 1024 < 8 
Escherichia coli OXA 512 128 >2048 16 
Escherichia coli TEM 180 < 8 32 >2048 < 8 
Klebsiella pneumoniae * 256 512 >2048 < 8 
Citrobacter freundii * < 8 64 512 < 8 
Salmonella enterica * < 8 < 8 64 < 8 
Pseudomonas aeruginosa PAO1 < 8 64 >2048 32 
Staphylococcus saprophyticus * < 8 < 8 >2048 < 8 
Staphylococcus epidermidis * < 8 < 8 256 16 
Staphylococcus aureus ATCC 43300 32 < 8 256 < 8 
Staphylococcus aureus ATCC 6538 32 < 8 256 < 8 
* clinical isolates  
 
Tetracycline was the antibiotic to which higher susceptibility was demonstrated, with 8/11 
(72%) of the tested bacteria presenting a MIC inferior to 8 µg/mL. To gentamicin and rifampicin, 
7/11 (64%) and 5/11 (45%), respectively, were susceptible to concentrations lower than 8 µg/mL. 
Ampicillin was the less effective antibiotic, with 6/11 (55%) presenting MIC values between 64 
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and 1024 µg/mL. Salmonella enterica was the most sensitive to the antibiotics assayed, with 
maximum MICs of 64 µg/mL.  
Ampicillin, a molecule considered to be one of the most successful β-lactamic, since it has 
multiple PBP targets,(Lewis 2013) showed less effectiveness against the tested bacteria, due to 
the intrinsic resistant mechanisms of the Gram-negative bacteria.(Lewis 2013) Pseudomonas 
aeruginosa had a MIC to this therapeutic agent higher than 2048 µg/mL, as expected, since this 
Gram-negative bacterium, in addition to the expression of active efflux pumps, is capable of 
producing β-lactamases that hydrolyze ampicillin. (Tenover 2006) Staphylococcus spp. are 
known to acquire resistance mechanisms through staphylococcal cassette chromosome mec 
(SCCmec), most commonly S. aureus. (Higashide et al. 2008) However, although rare, it has 
been reported antimicrobial resistance to ampicillin in S. saprophyticus. (Higashide et al. 2008) 
This might explain the result obtained for this strain (MIC >2048 µg/mL), which probably acquired 
this resistance mechanism, as well as the other Staphylococcus strains, to which ampicillin 
exhibited less efficacy (MIC= 256 µg/mL). This observation corroborates that, like other 
antibiotics, there is a tendency to lose efficacy over time, due to selective pressure exerted onto 
MDRB, translated in expression of more/novel resistance mechanisms. (Rossolini et al. 2014)  
Gentamicin, a bactericidal antibiotic from the aminoglycosides class, has been used over the 
past 20 years, being recommended for short-term and prolonged therapy, in most cases for 
serious Gram-negative infections. (Avent et al. 2011) However, the number of gentamicin-
resistant strains isolated have been increasing over the past 10 years, such as MDR P. 
aeruginosa, K. pneumoniae, E. coli and Acinectrobacter spp.. This might be explained by 
gentamicin constant misuse over the years.(Direção-Geral de Saúde 2014) In the present study 
is possible to verify less effectiveness of gentamicin against E. coli and K. pneumonia. This has 
already been reported by Magalhães et al. (2005). in E. coli and by Johnson et al. (1994) in K. 
pneumoniae, both associated with the enzymes 3-N-aminoglycoside acetyltransferases (AAC(3)) 
action of inactivate gentamicin. (Johnson, A.P., Burns, L., Woodford, N., Threlfall, E. J., Naidoo, 
J., Cooke, E. M. and George, R.C. 1994; Magalhães and Blanchard 2005) For S. aureus strains 
it was also observed less effectiveness of gentamicin, with MICs of 32 µg/mL, a higher value than 
the ones reported for MRSA, in the range of 16 and 24 µg/mL. (Vázquez et al. 2016) For S. aureus 
ATCC 6538 this value is higher than expected, probably because of features at cellular level, 
such as denser peptidoglycan layers. 
Tetracycline mechanism of action is similar to gentamicin, but has improved characteristics 
that enable its penetration in Gram-negative bacteria, making it more effective, as observed in 
the present results. (Chopra and Roberts 2001) It is also one of the most common alternative 
antibiotic used for penicillin-allergic patients. (Rubio-López et al. 2012) P. aeruginosa presents 
the higher MIC for tetracycline, which can be explained by the intrinsic mechanism of efflux pumps 
that actively pumps out this antibiotic. (Li, Livermore, and Nikaido 1994) 
Rifampicin is described to be one of the most broad-spectrum antibiotics, used as first-line 
therapy for Mycobacteria tuberculosis. (Alifano et al. 2015; Kohanski, Dwyer, and Collins 2010) 
As also being reported, rifampicin is considered more effective against Gram-positive bacteria, 
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achieving bactericidal effect in contract to the bacteriostatic action against Gram-negative 
bacteria. This difference is observed in the present results, being explained by the lower uptake 
of the molecule. (Kohanski, Dwyer, and Collins 2010) Considering the obtained results, rifampicin 
has demonstrated considerably MICs against Gram-negative bacteria. The emergence of 
resistance to Gram-negative bacteria has already been reported, (Goldstein 2014) and it 
constitutes a problem since it is a specific antibiotic for tuberculosis treatment. This translates the 
misuse of rifampicin for other therapies. 
 
After defining the antibiotics MIC, the antibacterial activity for each extract, and its 
representative bioactive compound(s), were tested against MDRB, in the same concentration 
range.  
 
4.2.2 – ENTB extract 
4.2.2.1 – MIC determination 
MICs were determined for ENTB extract and for TAs standard compounds against MDRB. 
Results are presented in Table 4.4. 
Table 4.4. MICs of ENTB extract and standard compounds of TAs: betulinic acid (BA), 
betulonic acid (BOA), oleanolic acid (OA) and ursolic acid (UA), against MDRB 
 MIC (µg/mL) 
Bacteria 
ENTB 
extract 
BA BOA OA UA 
Escherichia coli ATCC 25922 >2048 >2048 >2048 >2048 1024 
Escherichia coli OXA >2048 >2048 >2048 >2048 1024 
Escherichia coli TEM 180 >2048 >2048 >2048 >2048 1024 
Klebsiella pneumoniae* >2048 1024 >2048 1024 512 
Citrobacter freundii* >2048 1024 >2048 1024 512 
Salmonella enterica* >2048 1024 >2048 1024 512 
Pseudomonas aeruginosa PAO1 >2048 1024 >2048 1024 1024 
Staphylococcus saprophyticus* >2048 1024 >2048 1024 512 
Staphylococcus epidermidis* 128 512 >2048 1024 256 
Staphylococcus aureus ATCC 43300 64 512 >2048 512 128 
Staphylococcus aureus ATCC 6538 64 512 >2048 1024 256 
* clinical isolates 
 
Regarding TAs antibacterial activity, most bacteria were susceptible to BA, OA and UA, with 
MIC ranging from 512 and 1024 µg /mL for BA and OA, and 128 and 1024 µg/mL for UA. BOA 
did not presented antibacterial activity against this bacterial panel and in the range of 
concentrations tested. Previous studies regarding anti-MDRB activity of BA, UA and OA can be 
found in literature. A study performed by Fontanay et al.(Fontanay et al. 2008), using 
approximately the same conditions as the ones of the present work, studied the antibacterial 
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activity of UA, OA and BA against ATCC strains and clinical isolates. (Fontanay et al. 2008) 
Results showed that UA and OA presented better antibacterial performance against Gram-
positive bacteria, exhibiting MIC against S. aureus ATCC 29213 of 8 µg/mL and 32 µg/mL and 
against S. aureus ATCC 25923 of 8 µg/mL and 64 µg/mL, respectively. However they were not 
effective against clinical isolates, at the concentration range tested, which was to a maximum of 
256 µg/mL, while BA was devoid of any antibacterial activity against ATCC strains and clinical 
isolates. (Fontanay et al. 2008) Results obtained in the present work can overcome these results, 
where the concentrations range was higher, making it possible to determine the MIC for at least 
eight bacteria. Although MICs obtained were higher than the ones reported for UA and OA, these 
can be explained by the fact that Staphylococcus strains tested were different and so its 
characteristics, which may be linked to less susceptibility for these compounds. Nonetheless, the 
results obtained describe a good antibacterial activity, but the possible cytotoxicity factor should 
be kept in mind.  
Other studies have reported the extraction and isolation of these TAs from plant material and 
respective evaluation of their antibacterial activity in comparison to the commercially available 
ones. Differences between commercial (synthetized) and natural compounds (directly isolated 
from the plant) were observed, wherein isolated BA, UA and OA had higher antibacterial effect, 
with lower MIC, against ATCC strains and clinical isolates, than the commercially available forms. 
According to Nascimento et al.(2014), UA has higher effect against E. coli ATCC 25922 and S. 
aureus ATCC 6538, both also used in the present work, showing MIC of 64 µg/mL and 32 µg/mL, 
respectively. These results suggest that compounds extracted directly from plants have better 
performance against bacteria, probably due to the synthesis of these compounds as defense 
mechanisms of plants, which can be an explanation for the higher TAs MICs values obtained in 
the present work. BOA antibacterial activity is rarely reported in literature, showing inhibitory effect 
against E. faecalis (74% of inhibition) and S. aureus (51% of inhibition), which agrees with the 
obtained data.(Haque et al. 2014)  
The screening highlighted three Gram-positive bacteria as susceptible to ENTB extract: S. 
epidermidis, S. aureus ATCC 43300 and S. aureus ATCC 6538, with MIC of 128, 64 and 64µg/mL, 
respectively (Figure 4.1). For the last two strains, the results were considered as promising, since 
the MIC is very close to the one determined for the broad-spectrum antibiotics used in clinical 
field (MIC=32 µg/mL). 
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Figure 4.1. MTT assay results for ENTB extract against Staphylococcus spp.: a – S. 
epidermidis with MIC of 128 µg/mL; b – S. aureus ATCC 43300 with MIC of 64 µg/mL; c – 
S. aureus ATCC 6538 wth MIC of 64 µg/mL. 
ENTB extract effect is higher than that of TAs alone, which may be explained by synergistic 
or additive effect of the compounds in the extract. Different bioactive compounds in a mixture can 
interact to provide a combined effect, which is similar to the sum of the effects of the individual 
components (additive) or, the combination of bioactive compounds can exert a higher effect than 
the sum of the individual components (synergistic). (Ginsburg and Deharo 2011) In the present 
extract, TAs content was assessed and results showed that 350.68 mg of TAs are present per g 
of ENTB extract, more specifically 87.14 ± 13.15 mg of BOA/g of extract, 40.37 ± 8.42 mg of BA/g 
of extract, 116.17 ± 10.03 mg of OA/g of extract and 107.01 ± 9.99 mg of UA/g of extract. 
a 
b 
c 
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Regarding these results and the MICs obtained, it is possible to verify that 112.22 µg/mL of TAs 
are linked to S. aureus ATCC 43300 and S. aureus ATCC 6538 growth inhibition (specifically, 
27.88 µg /mL of BOA, 12.92 µg /mL of BA, 37.17 µg /mL of OA and 34.24 µg /mL of UA) and 
224.44 µg/mL for S. epidermidis growth inhibition (specifically, 55.77 µg /mL of BOA, 25.84 µg 
/mL of BA, 74.35 µg /mL of OA and 68.49 µg /mL of UA). 
The effect of ENTB extract in bacterial cell growth was assessed and results are represented 
in Figure 4.2.  
 
 
 
Figure 4.2. ENTB extract antibacterial effect in bacteria cell growth, in comparison to 
growth control (GC): a – S. epidermidis; b – S. aureus ATCC 43300; c – S. aureus ATCC 
6538. Each value is expressed as mean ± standard deviation of triplicates. In each column, 
different letters mean significant differences (p < 0.05). 
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S. epidermidis and S. aureus ATCC 6538 presented a gradual susceptibility to ENTB extract, 
i.e. as they were exposed to higher extract concentration, bacterial cell growth decreased. For S. 
epidermidis, ENTB extract exerted a higher statistically significant effect when compared to GC, 
starting at 64 µg/mL. For S. aureus ATCC 43300, the antibacterial effect is statistically significant 
from concentrations as low as 32 µg/mL, when compared to GC. 
ENTB extract presented a gradual antimicrobial effect against E. coli ATCC 25922, between 
512 and 2048 µg/mL (statistically significant different from GC), reaching maximum effect at 2048 
µg/mL, with 72% of growth inhibition. For S. enterica, similar behavior was observed, with 38% of 
inhibition achieved at 512 µg/mL and the maximum at 2048 µg/mL (78% of growth inhibition).  
The remaining MDRB tested did not present statistically significant differences after exposure 
to ENTB extract when compared to GC bacteria (without exposure to bioactive(s)).  
Regarding these results, ENTB extract was chosen to be included in the formulation. 
In what concerns other antibacterial activity studies described in literature and, to the best of 
our knowledge at the present time, there are no studies using ENTB extract. Outer bark extract 
of E. nitens was studied regarding its antibacterial activity in our research group, and results 
showed MIC ranging from 64 μg/mL for S. aureus strains to 512 μg/mL for E. coli and P. 
aeruginosa. (Parreira et al. 2015) These results show that the E. nitens outer bark and the total 
bark extracts possess similar antimicrobial activity against MRSA. However, the E. nitens outer 
bark extract has better performance against Gram-negative bacteria, which might be explained 
by the higher content in TAs. (Parreira et al. 2015) 
TAs antibacterial mechanism of action is not yet fully disclosed, but one hypothesis is that the 
antibacterial performance might be linked to the compounds lipophilic nature. (Barreto et al. 2014) 
Due to this, TAs interaction with the hydrophobic sites on the plasma membrane and on the outer 
membrane of Gram-negative bacteria is facilitated, causing changes in the bacterial membrane 
namely: increase of permeability; loss of integrity; loss of cytoplasmic content; dissipation of the 
proton-motive force; lysis and cell death. (Barreto et al. 2014) Also, it is thought that OA and UA 
might have PBP as target, which is involved in the peptidoglycan synthesis, due to the higher 
susceptibility of Gram-positive bacteria to these compounds, when compared with Gram-negative 
bacteria. (Kurek et al. 2012) 
 
In order to assess if the ENTB extract MIC and/or the concentration immediately above had 
bacteriostatic or bactericidal effect, MBCs were determined. 
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4.2.2.2 – MBC determination 
ENTB extract presented MIC for the following MDRB: S. epidermidis; S. aureus ATCC 43300 
and S. aureus ATCC 6538 and therefore, MBCs were determined for these bacteria. Results are 
presented in Table 4.5. 
Table 4.5. MBC of ENTB extract against MDRB 
Bacteria MBC (µg/mL) 
S. epidermidis* >2048 
S. aureus ATCC 43300 256 
S. aureus ATCC 6538 >2048 
* clinical isolates 
 
In the present assay, it was possible to assess if ENTB extract exerted bactericidal or 
bacteriostatic effect at the MIC. Results showed that ENTB extract has bacteriostatic effect 
against S. epidermidis and S. aureus ATCC 6538 at the MIC., which means that ENTB extract 
inhibits bacterial growth of these strains, keeping them in the stationary phase of growth. 
Bactericidal effect was observed for S. aureus ATCC 43300, at 256 µg/mL. This result means 
that ENTB extract exerts bacteriostatic effect at the MIC but is also capable of killing at 
concentrations above.  
Regarding the study of Parreira et al.(2015), referenced above, using E. nitens outer bark 
extract, the MBC obtained in the present work for S. aureus ATCC 43300 is higher, which 
suggests less bactericidal effect of ENTB extract. This result can be explained by the higher 
content of TAs in the outer bark extract, translated in higher antibacterial effectiveness. (Parreira 
et al. 2015) 
 
After MICs and MBCs determination, time-kill assay was performed.  
 
4.2.2.3 – Time-kill assay 
Time-kill assay was performed only for susceptible bacteria to ENTB extract: S. epidermidis, 
S. aureus ATCC 43300 and S. aureus ATCC 6538 (Figure 4.3). The assay was performed at 2, 
6, 24 and 48 hours of exposure to ENTB extract, in the same range of concentrations used for 
MIC determination (8 µg/mL - 2048 µg/mL). MICs for ENTB extract were again assessed for each 
bacteria and, while performing this assay, changes to the previously determined MICs were 
observed for S. epidermidis and S. aureus ATCC 6538, 2048 µg/mL to 128 µg/mL and 1024 
µg/mL to 64 µg/mL, respectively. A possible explanation for this observation might be related to 
TAs degradation in the ENTB extract during storage, which would explain the decrease in 
antibacterial activity. However, and because for one of the tested bacteria the same MIC was 
determined and concordant to the previously obtained, changes regarding the bacterial strains 
might also have occurred in what concerns susceptibility. Therefore, sub-MIC ENTB extract 
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concentrations of 1024 µg/mL, 32 µg/mL and 512 µg/mL were chosen to evaluate 
bacteriostatic/bactericidal effect against S. epidermidis, S. aureus ATCC 43300 and S. aureus 
ATCC 6538, respectively.   
Assays were performed in triplicates. Results for sub-MIC were used to evaluate behavior 
along the time (Figure 4.3).  
 
   
   
  
 
The 3 tested Staphylococcus spp. strains showed different behavior. S. epidermidis cell 
growth gradually increased over time, starting with 3% until 79%, at 48h, which means that ENTB 
extract exerts higher effect up to 2h of exposure, decreasing after that. Inhibition of S. aureus 
ATCC 43300 was higher until 6h of exposure, with only 13% of bacterial growth, but afterwards 
the antibacterial effect was gradually lost, being residual after 48h. Lastly, ENTB extract inhibitory 
effect against S. aureus ATCC 6538 was more pronounced between 6h and 24h of exposure, 
with only 11% of bacterial growth, but an accentuated increase in bacterial growth occurred next, 
being this trend visible up to 48h.  
These results were expected since ENTB extract exerts bacteriostatic effects against S. 
aureus ATCC 6538 and S. epidermidis, as determined by the MBC assay, meaning that bacterial 
growth is only temporarily inhibited by the extract and cell death is not induced. Nonetheless, the 
bacteriostatic effect of ENTB extract is maintained until 24h, being then required a new exposition 
to ENTB, in order to maintain bacterial growth at minimum levels.  
Although ENTB extract had bactericidal action against S. aureus ATCC 43300 at 256 µg/mL, 
at a sub-MIC concentration (32 µg/mL), this effect was not observed. However, when evaluating 
MIC and MBC over time for this Staphylococcus strain, it was possible to observe that the 
inhibitory and bactericidal effect was maintained until 48h of exposure, highlighting ENTB 
potential against S. aureus ATCC 43300. This S. aureus strain is the most used in antibacterial 
Figure 4.3. Time-kill curves for ENTB extract 
for sub-MIC values (% of growth in 
comparison to GC): a – S. epidermidis 
growth at 1024 µg/mL; b – S. aureus ATCC 
43300 growth at 32 µg/mL; c – S. aureus  
ATCC 6538 growth at 512 µg/mL. Each value 
is expressed as mean ± standard deviation 
of triplicates 
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studies as reference strain to MRSA. On the other hand, S. aureus ATCC 6538 is used as strain 
reference for Methicillin-sensitive Staphylococcus aureus (MSSA), so it was expected that this 
strain would be more susceptible to ENTB extract than S. aureus ATCC 43300, which was not 
observed. This difference could be related to the TAs mechanism of action at the cellular level 
against S. aureus strains.  
Studies related with effectiveness of antibacterial agents over time are widely reported in 
literature. However, exposure time to the antibacterial agents generally does not exceed 24h, 
being the ones using 48h rare. In the present study, the exposure time was longer, in order to 
further evaluate the effectiveness and potential of ENTB extract. In what concerns TAs 
antibacterial effectiveness over time, it is reported that OA and UA lose their antibacterial effect 
after 2h of exposure, against both S. aureus and S. epidermidis, using sub-MIC concentrations. 
(Kurek et al. 2012) A study by Wang et al. (2016) demonstrated antibacterial effectiveness of UA 
over time, at sub-MIC concentration against MSSA (MIC of 16 µg/mL) and MRSA (MIC of 64 
µg/mL), showing the results that the antibacterial effect is lost after 6h of exposure, for both 
bacteria, which is in agreement with data obtained in the time-kill assay. (Wang et al. 2016)  
 
 
4.2.2.4 – Synergistic activity (antibiotic plus extract) 
Synergistic activity between ENTB extract and antibiotics was tested to assess if the ENTB 
extract might be used as a coadjuvant to broad-spectrum antibiotics, maximizing their effect. 
Rifampicin, gentamicin, ampicillin and tetracycline, were tested against S. epidermidis, S. aureus 
ATCC 43300 and S. aureus ATCC 6538. MICs for antibiotics were again determined. Factorial 
inhibitory concentration index (FICI) was determined to classify interaction between ENTB extract 
and antibiotics. Results are shown in Table 4.6.  
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Table 4.6. MIC (expressed in µg/mL) of antibiotic, ENTB extract (MIC) and ENTB extract together 
with antibiotics (MICa) against Staphylococcus spp. Factorial inhibitory concentration index (FICI) is shown 
for all the mixtures.  Interactions are expressed as synergistic (S), partially synergistic (PS), additive (Ad), 
indifferent (I) or antagonist (A). 
 
  Bacteria 
  S. epidermidis* S. aureus ATCC 43300 S. aureus ATCC 6538 
ENTB extract MIC 2048 64 1024 
Rifampicin MIC 32 16 64 
 MICa 8 <2 64 
 FICI 0.25 (S) <0.125 (S) 1 (Ad) 
Gentamicin MIC 512 >256 32 
 MICa 256 16 16 
 FICI 0.5 (S) <0.06 (S) 0.5 (S) 
Ampicillin MIC >2048 128 256 
 MICa >2048 64 >2048 
 FICI >1 (I/A) 0.5 (S) >8 (A) 
Tetracycline MIC 32 >256 16 
 MICa 16 16 16 
 FICI 0.5 (S) <0.06 (S) 1 (Ad) 
* clinical isolate 
 
Regarding FICI values, calculations were performed according to Equation 1 (3.3.2.3) and 
interpreted as: synergistic, if FICI ≤ 0.5; partially synergistic, if 0.5 < FICI < 1; additive, if FICI = 1; 
indifferent, if 1 < FICI ≤ 4 and antagonistic, if FICI > 4.  
Synergy was observed for the majority of antibiotics when in combination with ENTB extract 
against MDRB, and a particularly high synergistic effect was observed against S. aureus ATCC 
43300. S. epidermidis also presented synergistic effect when using ENTB extract in combination 
with rifampicin, gentamicin and tetracycline. For ampicillin+ENTB extract against S. epidermidis, 
results are inconclusive, since the MIC is >2048 µg/mL. Finally, for S. aureus ATCC 6538 only 
gentamicin+ENTB extract presented synergistic effect, while the remaining mixtures presented 
antagonistic effect. Since TAs structures are quite different from those of antibiotics, the 
mechanism of action and/or target may be different and, therefore, other pathways/targets might 
be involved in bacterial inhibition.  
As already described, natural compounds are good candidates to be used in drug 
combinations, achieving favorable results such as enhanced efficacy, decrease dosage and 
delayed development of drug resistance. (Ginsburg and Deharo 2011) Previous studies reported 
excellent outcomes when using TAs in combinations with antibiotics. A synergistic study, 
performed by Wang et al.(2016), showed that UA and OA had a synergistic effect when combined 
52 
 
with ampicillin and tetracycline against MRSA and MSSA (Wang et al. 2016). A study performed 
by Chung et al.(2011)  reported synergistic effect between BA and methicillin against S. aureus 
ATCC 43300. (Chung, Navaratnam, and Chung 2011) The present study suggests that ENTB 
extract might be used as coadjuvant or as part of drug combinations, due to the synergistic effect 
observed. These are promising results and in the future, it would be interesting to assess 
effectiveness over time (time-kill assay) of the combinations used. 
 
4.2.3 – Cynara cardunculus leaf (CcL) extract 
MICs were determined for CcL extract against MDRB and results are represented in Table 
4.7. 
Table 4.7. CcL extract MIC against MDRB. 
Bacteria MIC (µg/mL) 
Escherichia coli ATCC 25922 >2048 
Escherichia coli OXA >2048 
Escherichia coli TEM 180 >2048 
Klebsiella pneumoniae* >2048 
Citrobacter freundii* >2048 
Salmonella enterica* 2048 
Pseudomonas aeruginosa PAO1 >2048 
Staphylococcus saprophyticus* >2048 
Staphylococcus epidermidis* >2048 
Staphylococcus aureus ATCC 43300 2048 
Staphylococcus aureus ATCC 6538 >2048 
 * clinical isolates 
 
CcL extract only presented inhibitory effect against S. aureus ATCC 43300 and S. enterica, 
with MIC of 2048 µg/mL, for both (Figure 4.4). As previously determined, the major bioactive 
compound in CcL extract, cynaropicrin, represents 455.2 mg/g of extract and has a MIC against 
S. aureus ATCC 43300 of 128 µg/mL. (Patrícia Alexandra Bogango Ramos 2015) At the MIC, 
182.1 µg of cynaropicrin are present, and, therefore, a better antibacterial performance was 
expected, since the MIC obtained, 2048 µg/mL, is 16 times higher. A possible explanation for this 
might be the fact that cynaropicrin antibacterial activity may be partially or completely inhibited by 
other extract compounds, in an antagonistic effect behavior.  
  
53 
 
 
 
 
Figure 4.4. MTT assay results for CcL extract: a – S. aureus ATCC 43300 with MIC of 
2048 µg/mL; c – S. enterica with MIC of 2048 µg/mL. 
The inhibitory effect of CcL extract against S. aureus ATCC 43300 is represented in Figure 
4.5.  
 
Figure 4.5. CcL extract antibacterial effect against S. aureus ATCC 43300. Results are 
expressed in comparison to growth control (GC). Each value is expressed as mean ± 
standard deviation of triplicates. In each column, different letters mean significant 
differences (p < 0.05) between different samples (Tuckey’s test). 
a 
b 
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CcL extract presented a gradual inhibitory effect, beginning this effect to be statistically 
different from GC at 256 µg/mL, but the maximum inhibitory effect was obtained at 2048 µg/mL.  
No inhibitory effect of CcL extract against the remaining tested bacteria was observed, 
exception made for S. enterica (Table 4.8). 
 Studies focusing on the use of CcL extract and its antibacterial activity, using the microbroth 
dilution method, are rare in the literature. In a recent study, the CcL extract antibacterial activity 
against P. aeruginosa and MRSA was determined, being determined that it was effective against 
MRSA at 1024 µg/mL, a MIC lower than the one obtained in the present work. (Patrícia Alexandra 
Bogango Ramos 2015) This result may be related to differences in strains characteristics, which 
confers to S. aureus ATCC 43300 less susceptibility. 
Given that just two bacteria were susceptible to CcL extract and with a MIC of 2048 µg/mL, a 
relatively high value, CcL extract was not chosen to undergo further studies regarding the 
formulation design.   
 
4.2.4 – DOP extract 
MICs were determined both for DOP extract and for the standard phenolic compounds against 
MDRB. Results are presented in Table 4.8. 
 
Table 4.8. MIC for DOP extract and for standard compounds of phenolic compounds 
hydroxytyrosol (H), tyrosol (T) and oleuropein (O). 
Bacteria 
MIC (µg/mL) 
DOP extract O HT T 
Escherichia coli ATCC 25922 >2048 >2048 >2048 >2048 
Escherichia coli OXA >2048 >2048 >2048 >2048 
Escherichia coli TEM 180 >2048 >2048 1024 >2048 
Klebsiella pneumoniae * >2048 >2048 1024 >2048 
Citrobacter freundii* >2048 >2048 >2048 2048 
Salmonella enterica* >2048 >2048 n.d. >2048 
Pseudomonas aeruginosa PAO1 >2048 >2048 n.d. >2048 
Staphylococcus saprophyticus* >2048 >2048 n.d. 2048 
Staphylococcus epidermidis* >2048 >2048 1024 2048 
Staphylococcus aureus ATCC 43300 >2048 >2048 1024 >2048 
Staphylococcus aureus ATCC 6538 >2048 n.d. 1024 >2048 
* clinical isolates; n.d. – not determined. 
 
In what concerns antibacterial activity, given the amount of phenolic compounds obtained 
(4.1.1) and in accordance to what is described in the literature (Wichers, Soler-rivas, and Espı 
2000), better DOP antibacterial performance was expected, since the MICs ranged between 1024 
and 2048 µg/mL. Oleuropein did not show MIC against the MRDB panel tested, while tyrosol only 
presented inhibitory effect against 3/11 (27%) of the MDRB, with MIC of 2048 µg/mL. 
Hydroxytyrosol showed a slightly better inhibitory effect than the other two compounds, with MIC 
55 
 
of 1024 µg/mL for 5/11 (45%) of MDRB. Concerning what is described in the literature regarding 
the antibacterial activity of phenolic compounds, hydroxytyrosol is the one with better antibacterial 
efficacy, being reported in a recent study a MIC of 400 µg/mL against S. aureus ATCC 25923 and 
800 µg/mL against E.coli ATCC 25922. (Lim et al. 2016) In the same study, oleuropein 
antibacterial performance was also assessed, exhibiting less antibacterial activity, with MIC of 
3200 µg/mL for E. coli ATCC 25922 and 800 µg/mL for S. aureus ATCC 25923. (Lim et al. 2016) 
Oleuropein lower antibacterial activity is explained by the lack of ability to penetrate the cell or 
reach the target site due to the presence of a glycosidic group. (Lim et al. 2016) In other different 
studies, tyrosol antibacterial activity was assessed and results showed MIC higher than 5 mg/mL. 
(Aissa et al. 2012; Chakroun et al. 2013) This difference between hydroxytyrosol and oleuropein 
antibacterial performance is mainly attributed to the lack of an o-diphenol structure, which confers 
the antibacterial activity to the molecules. (Tuck, Tuck, and Hayball 2015) In the present study, it 
was possible to assess that Staphylococcus strains tested were less susceptible to hydroxytyrosol 
than S.aureus ATCC 25923 with MIC of 1024 µg/mL. However E. coli ATCC 25922, also used in 
the study mentioned, was not susceptible at the concentration reported as MIC. The explanation 
for these inconsistent results is not clear, but it is possible that interferences occurred with the 
MTT assay. Obtained results for oleuropein are concordant with what is described, since S. 
aureus ATCC 25923 is more susceptible than the other strains tested. (Lim et al. 2016) For 
tyrosol, the MIC against Citrobacter freundii, S. saprophyticus and S. epidermidis was established 
at 2048 µg/mL.  
The MICs that were not determined were due to a detected limitation for the use of the MTT 
assay, since the purple color appeared in higher concentrations of the tested compound but not 
on the lowest. This observation might be related to the fact that MTT reacts with antioxidant 
compounds, resulting the purple colored formazam product. (Bruggisser et al. 2002) In future 
work, Alamar blue bioassay should be considered as an alternative to the MTT assay. 
(Rampersad 2012)  
Interestingly, a closer observation of the obtained results for DOP bacterial growth inhibition, 
in comparison to GC, showed an unexpected behavior. As the DOP extract concentration 
increased, the bacterial growth also increased, whereas it was expected to observe growth 
reduction. These results led to the question of whether the sugars present in the extract would be 
interfering with the antibacterial activity, being used as Carbon source for bacterial growth. 
Therefore, the reducing sugars were quantified and results are presented in section 3.4.3. 
There are few studies that report the antimicrobial activity of olive pomace and, those 
available, are mainly focused on ecological and agronomic applications. Studies using DOP 
extract as an anti-MDRB agent were not found in literature, being the present work, to the best of 
the knowledge, the first to report that DOP phenolic extract has no anti-MDRB activity up to 2048 
µg/mL. 
Given these results, DOP extract was not chosen to pursue further tests regarding formulation 
design. 
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4.3 – Reducing sugars quantification in the extract  
Reducing sugars were determined to assess if this parameter could be interfering with the 
extracts antibacterial activity. Triplicates were made for each extract. Xylose and glycose were 
used as standards compounds, being results expressed in milligram of each reducing sugar per 
gram of extract (Table 4.9).  
 
Table 4.9. Reducing sugars (RS) content in xylose (Xyl) and glycose (Gly) in ENTB, 
DOP and CcL extracts. Each value is expressed as mean ± standard deviation of 
triplicates. In each column different letters mean significant differences (p < 0.05) 
between different samples (Tuckey’s test). 
 
Extract 
Total reducing sugars content (mg RS/g of extract) 
Xyl Gly 
ENTB 45.26 ± 2.68 c 45.30 ± 3.06 c 
DOP 70.88 ± 1.78 a 74.59 ± 2.04 a 
CcL 60.20 ± 2.17 b 62.38 ± 2.48 b 
 
DOP extract was the one with higher content in reducing sugars, xylose and glycose, being 
ENTB extract the one with lower concentration of both sugars. Results presented statistically 
significant differences between the three tested extracts.  
A mixture of xylose and glycose was tested against Staphylococcus spp. to observe if the 
growth profile was similar to the one previously obtained with DOP extract, which was confirmed. 
Therefore, the DOP extract, despite its composition in bioactives with recognized antibacterial 
potential, is not a suitable candidate as an anti-MDRB option, since bacteria are able to use this 
extract as Carbon source for growth. 
 
4.4 – Formulation Design 
4.4.1 – Preformulation and characterization studies 
During preformulation studies, several excipients were tested, aiming to achieve an ENTB 
extract aqueous solution. Ethanol was used to solubilize ENTB extract according to previous 
studies performed by our research group. Regarding the surfactants, Emulcin and propylene 
glycol, were unable to stabilize the formulation, occurring the extract precipitation and, therefore, 
were discarded as options. TAGATCH40 contributed to obtain a clear and limpid formulation and 
thus, it was selected as surfactant in this first phase. Three formulations were prepared with equal 
excipients, only changing the TAGATCH40 percentage. The composition of these formulations 
is presented in Table 4.10.(Rowe, Sheskey, and Quinn 2009)  
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Table 4.10. Qualitative and quantitative composition of ENTB formulations. 
Ingredients  
(w/w %) 
Functions 
Formulations 
A B C 
ENTB extract Active substance 0.1 0.1 0.1 
Ethanol Cosolvent 4 4 4 
TAGATCH40 Surfactant 5 2 0 
Ascorbic acid Antioxidant 0.1 0.1 0.1 
Potassium 
sorbate 
Antimicrobial 
preservative 
0.2 0.2 0.2 
Purified water Solvent 90.6 93.6 95.6 
 
After preparation, the formulations were characterized regarding the main quality control 
parameters (Table 4.11).  
 
Table 4.11. Quality control of ENTB formulations. Each value of viscosity is expressed as 
mean ± standard deviation of duplicates. Different letters mean significant differences   
(p < 0.05) between samples (Tuckey’s test). 
η - Viscosity; * - not determined;  
 
All formulations presented the ENTB extract characteristic odor (eucalyptus). The 
appearance and color of formulations A, B and C depended on TAGATCH40 amount: 
formulation A, the one with a higher percentage of this excipient, was the more limpid and the one 
that presented an intensified color (Figure 4.6). Considering the appearance of formulation C, 
probably the ENTB extract was suspended in this vehicle, since it turned to an opaque white 
colored formulation. Density was directly dependent on TAGAT CH40 amount as well. pH value 
of the three formulations was 5, which is ideal for topical delivery products (4.5-7.5) and for the 
potassium sorbate preservative activity against yeasts and molds. (Daudt et al. 2015; Rowe, 
Sheskey, and Quinn 2009)  
 
 
  Organoleptic properties 
Density 
(g/mL) 
pH η (Pa.s) at 20ºC 
  Appearance Color Odor 
F
o
rm
u
la
ti
o
n
 
A Limpid 
Light 
green 
Extract 
characteristic 
1.048 5 * 
B 
Lightly 
limpid 
Light 
green 
Extract 
characteristic 
0.997 5 
1.72×10-3 a 
(±8.63×10-5) 
C Opaque White 
Extract 
characteristic 
0.993 5 
1.28×10-3 b 
(± 8.21×10-5) 
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Figure 4.6. Visual appearance of the three formulations designed: a – Formulation A (5% 
of TAGATCH40); b – Formulation B (2% of TAGATCH40); c – Formulation C (without 
(0%) TAGATCH40). 
Formulations B and C presented statistically significant differences of viscosity, confirming 
that TAGATCH40 had an important effect on physical properties of the tested formulations. 
The flow curves of these formulations are represented in Figure 4.7.  
 
 
Figure 4.7. Flow curves of formulations B and C at different shear rates from 10 to 200s-1 
at 20°C. Each value is expressed as mean ± standard deviation of duplicates. 
According to Figure 4.7, both formulations presented a linear tendency, correspondent to a 
Newtonian fluid, as theoretically expected for aqueous solutions. (Banker and Rhodes 2002) 
  
a b c 
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4.4.2 – Antibacterial activity of formulations A, B and C 
Antibacterial activity was performed for all formulations against S. aureus ATCC 43300, at 
5.6 and 90% range. Solution control (SNC), i.e. the vehicle without active substance and 
antimicrobial agent, was a very important parameter to be assessed in order to ensure that 
antibacterial activity observed was merely attributed to ENTB extract. Results are showed in 
Figure 4.8. 
 
   
  
  
 
Results highlighted that SNC of formulations A and B (composed by ethanol, TAGATCH40 
and purified water) exerted antibacterial effect, translated in only 34% and 84% of growth (66 and 
16% of growth inhibition, respectively), with statistically significant differences when compared to 
GC. On the contrary, the SNC of formulation C, composed only by ethanol and purified water, did 
not present antibacterial effect, being statistically equal to GC. This meant that the formulation 
effect observed against bacteria was only due to ENTB extract. In particular, all the percentages 
tested showed an antibacterial effect with statistically significant differences in comparison to GC. 
Regarding each percentage, it is possible to observe that 22.5 and 45% presented a higher 
inhibitory effect against S. aureus ATCC 43300, statistically significant different from the others. 
These results might be related to the bioavailability of the formulation in aqueous media and its 
interaction with bacteria in the interface zone.  
Results highlighted formulation C as the one with better antimicrobial activity and without 
interference of vehicle in the final antibacterial performance. The antimicrobial effect of the vehicle 
in other formulations might be explained by the fact that nonionic surfactants, like TAGATCH40, 
Figure 4.8. Antibacterial effect of the 
formulations designed: (a) formulations A; (b) 
formulation B and; (c) formulation C, against S. 
aureus ATCC 43300. Results are expressed as 
cell growth (%) in comparison to growth control 
(GC) and solution control (SNC). Each value is 
expressed as mean ± standard deviation of 
triplicates. In each column different letters 
mean significant differences (p < 0.05) between 
different samples (Tuckey’s test). 
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eventually have toxic effect against bacteria following two mechanisms: disruption of the cellular 
membrane and/or reactions of the surfactant with enzymes essential to cell functioning. (Song 
and Bielefeldt 2012) Given these results, only Formulation C was chosen to proceed to further 
studies. 
 
 
4.4.3 – Stability studies 
Stability studies of the Formulation C were performed at different temperatures (room 
temperature (RT) approximately 25°C and 4°C) evaluating selected properties (organoleptic 
characteristics, pH, microbiologic assay, viscosity and identification and quantification of active 
substances) (Table 4.12).  
 
Table 4.12. Stability study of formulation C at different temperatures: room temperature 
(RT) and 4°C. 
Month Storage 
Organoleptic characteristics 
pH 
Microbiologic 
assay Appearance Color Odor 
1 
RT Opaque W EC 5 NG 
4°C Opaque W EC 5 NG 
2 
RT Opaque W EC 5 NG 
4°C Opaque W EC 5 NG 
3 RT Opaque W EC 5 NG 
 4°C Opaque W EC 5 NG 
4 RT Opaque W EC 5 NG 
 4°C Opaque W EC 5 NG 
5 RT Opaque LY EC 5 NG 
 4°C Opaque W EC 5 NG 
 
Color: LY – light yellow/ W – white; Odor: EC – Extract characteristic odor; Microbiologic assay: NG – No 
growth 
 
Formulation C maintained its appearance, pH and microbiologic assay without alterations 
over the course of the stability studies (5 months). This formulation only suffered color alterations 
at RT and during the last month, being therefore considered more stable when kept at 4° C. 
Unfortunately, rheological behavior was not monitored due to limitations of formulation amount.  
Considering the identification and quantification of active substances, initial concentrations of 
TAs assessed by HPLC and conversion to actual percentage in formulation (0.1%) are shown in 
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Table 4.13. ENTB extract concentrations over time were determined, and results are shown as 
ratio concentration : initial concentration (Figure 4.9). 
 
Table 4.13. Initial concentration (C0) of TAs: betulinic acid (BA), betulonic acid (BOA), oleanolic acid (OA) 
and ursolic acid (UA) at 0.7% used for HPLC analysis, and 0.1% used in the formulation. Each value of 
viscosity is expressed as mean ± standard deviation of triplicates. Different letters mean significant 
differences (p < 0.05) between different samples (Tuckey’s test). 
 
 
ENTB extract 
(%) 
C0 (µg/mL) 
BOA BA OA UA 
0.7 
207.38 ab 
(± 63.42) 
176.75 b 
 (± 20.28) 
289.68 a 
(± 13.81) 
231.85 ab 
(± 20.96) 
0.1 
29.63 ab 
(± 9.06) 
25.11 b 
(± 2.90) 
41.24 a 
(± 1.97) 
32.98 ab 
(± 2.99) 
 
 
 
 
Figure 4.9. Quantification of TAs in formulation C over time represented as ratio 
concentration : initial concentration (C/C0): a – Formulation stored at RT; b – Formulation 
stored at 4°C. Each value is expressed as mean of triplicates. 
Results showed a decrease in TAs concentration, approximately after 20 days of storage, at 
both temperatures. This decrease is translated in a reduction of 70 and 66% in the TAs average, 
both at RT and 4°C, respectively (specifically, 83% of BOA, 72% of BA, 69% of OA and 55% of 
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UA at RT, and 77% of BOA, 70% of BA, 63% of OA and 53% of UA at 4°C). These results are 
not according to the Portuguese Pharmacopeia, in which a formulation is considered chemically 
stable when the percentage of the active substance remains up until 90% of initial concentration. 
(Farmacopeia Portuguesa 2005) Therefore, Formulation C is not considered chemically stable at 
both RT and 4°C. Moreover, it is likely that the antimicrobial activity of the formulation will also 
decrease, due to the TAs concentration fluctuation. The occurrence of chemical reactions in 
compounds that constitute ENTB extract might be an explanation to the decrease observed, to 
which the color changes in the formulation may also be related. 
Overall, formulation C stored at 4°C seems to be the best option regarding all parameters 
studied. However, some aspects need to be further explored, such as solubility and how to 
enhance the stability of these bioactive compounds at RT, since ideally the formulation should be 
stable at RT, concerning its ease of use in healthcare facilities. 
 
4.4.4 – Sensorial evaluation  
Sensorial evaluation is considered a quality guarantee since this analysis integrates 
multidimensional measures. (Daudt et al. 2015) The advantage of this analysis is the ability to 
evaluate how many tasters like and dislike, and more importantly, allows to refine sensorial 
characteristics of the formulation and detect failures or aspects that consumers identify that need 
improvement. (Daudt et al. 2015) 
The present analysis involved both male and female participants with different ages. Different 
parameters (general appreciation, touch, spread, feeling and final appreciation) were evaluated 
and classified using a scale from 1 to 5, where 1 represents the lower level of appreciation and 5 
the maximum (Appendix 1). Regarding the consistency, the scale refers to fluidity, where 1 
represents the maximum level and 5 the lower level. Sensorial evaluation is represented in Figure 
4.10. 
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Figure 4.10. Sensorial evaluation of Formulation C (n=42). Five parameters were 
evaluated, being classified from 1 (not like at all) to 5 (really like). Results are expressed 
in percentage, considering the total number of participants in each evaluation. 
Formulation C presented diverged opinions regarding the initial analysis, where 40% of 
tasters liked (3) and 40% liked much (4). The next four parameters were evaluated, where 38% 
of tasters liked much (4) the touch, 57% thought it was really easy (5) to spread, 26% found the 
formulation very fluid (1) and 43% liked (3) the feeling on the skin. 26% of tasters assigned level 
4 of appreciation regarding consistency. This high difference between levels might be associated 
to the scale of consistency, which was different from the others, and some misunderstandings 
might have occurred. Lastly, 40% of tasters liked much formulation C in the final general 
appreciation. Interestingly, formulation C had a median level of appreciation on the initial 
evaluation, but at the end it obtained a good evaluation. This result demonstrates that appearance 
is a very significant parameter for consumers. 
Suggestions and comments were quite welcome during this evaluation, and the most 
common were related to: improvement of consistency; color (turn to colorless); more oily 
formulations and maintaining the eucalyptus smell in the hands to give the “fresh-feeling”. 
Regarding the improvement of consistency, it should be noticed that the preferential rheological 
behavior for topical formulations is pseudoplastic, i.e., consistency must be sufficient to be well 
spread but not too liquid, which is not observed for Formulation C. Moreover, the formulation 
rheological behavior must also be adjusted to the packaging material of the pharmaceutical 
product and all of these features must be taken in account when refining the consistency 
characteristic. An alternative dosage form to the hydroalcoholic solution, like in formulation C, 
might be gels or extemporaneous formulation. Gels are usually more appreciated by 
tasters/consumers in what concerns consistency and rheological behavior, while 
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extemporaneous formulation possesses advantages in what concerns physico-chemical stability 
and storage conditions.  
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5 – Conclusion & Future perspectives 
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The main objective of this work was to establish the foundations for the development of a 
novel antiseptic formulation based on natural extracts. For that purpose, the antibacterial activities 
of three industry by-products (biomasses) were studied and ENTB extract was selected as the 
one with best antibacterial performance, with MIC concentrations against Staphylococcus spp. 
between 128 and 64 µg/mL. DOP extract and CcL extract anti-MDRB activity did not meet the 
requirements to proceed to preformulation tests. Moreover, ENTB extract also showed to be 
bactericidal against S. aureus ATCC 43300 at a concentration of 256 µg/mL, being this effect 
maintained until, at least, 48h of exposure. Promising results were obtained when ENTB extract 
was tested in combination with antibiotics, demonstrating synergistic activity, particularly against 
Staphylococcus spp., which highlighted its usefulness as a possible coadjuvant to the 
conventional available antibiotherapy. Thus, ENTB extract was formulated with different vehicles 
in preformulation studies to further evaluate its potential as an active substance of an anti-MDRB 
formulation. Preformulation design allowed to assess the ENTB extract potential when included 
in a hydro-alcoholic solution without non-ionic tensioactive TAGAT®CH40 (Formulation C). 
Antibacterial activity assay of Formulation C, tested against Staphylococcus spp., showed 
promising results, with growth inhibition of 97%, approximately, when exposed to 45% of 
formulation. Overall, the main purpose of this work was accomplished.  
As future perspectives, several items still require to be investigated to further pursue this 
phytopharmaceutical research line, which yielded promising results. The fact that there was a 
decrease in TAs concentrations and changes in the final formulation color over time, indicated a 
lack of ENTB extract chemical stability in aqueous solution, which suggests that other dosage 
forms, such as gels or an extemporaneous formulation, may present advantages, mainly 
regarding stability issues and storage conditions. Furthermore, the formulation design 
(composition, rheology and stability studies) could be more explored since the vehicle of initial 
solutions was modified according to microbiological results. Also, cytotoxicity assays with 
epithelial cell lines and establishing the ENTB mechanism of action are also required. Further 
aspects that may be explored are other possible uses of an ENTB-based-formulation, namely its 
use as an antifungal agent or as a detergent for surfaces sanitation within health-care facilities. 
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Appendix 1 – Sensorial evaluation questionnaire for formulation C 
 
 
 
 
Análise sensorial de uma formulação tópica 
 
Nome__________________________________________________________________ 
 
Data: _____/_____/______      Idade:_______  
 
Descrição da formulação: Solução hidroalcoólica tendo como princípio ativo extrato natural da 
casca de Eucalyptus nitens.  
Este estudo tem como objetivo saber qual a sua opinião e preferência em relação à formulação 
fornecida. Peço que siga as instruções de aplicação do produto e responda ao questionário. 
Muito obrigada pela colaboração! 
 
Aplicação do produto 
1. Aplicar a formulação nas mãos e espalhar 
2. Massajar até a formulação desaparecer 
3. Responder ao questionário 
 
Questionário 
O questionário tem 6 perguntas às quais é atribuída uma escala de 1 a 5. Deve assinalar com 
um  qual corresponde a sua opinião. 
 
1. Antes de aplicar, qual a sua opinião geral sobre a formulação (Ex: Cor, cheiro, 
aparência)?  
1 2 3 4 5 
     
(1: Não gosto nada  5: Gosto muito) 
2. Qual a sensação ao tocar na formulação? 
1 2 3 4 5 
     
(1: Nada agradável  5: Muito agradável) 
3. Como considera o espalhamento da formulação? 
1 2 3 4 5 
     
(1: Muito difícil  5: Muito fácil)  
4. Classifique a consistência. 
1 2 3 4 5 
     
(1: Muito líquido  5: Muito viscoso)  
5. Qual a sensação que o produto lhe causou após ser aplicada? 
1 2 3 4 5 
     
(1: Desagradável  5: Muito agradável) 
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6. Após aplicação, qual a sua opinião geral sobre a formulação (Ex: cheiro na pele)? 
1 2 3 4 5 
     
(1: Não gosto nada  5: Gosto muito) 
7. Sugestões (Facultativo) 
 
 
 
 
